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Abstract 
KAVITA PRAVEEN: Modeling human spinal muscular atrophy mutations in 
 Drosophila melanogaster 
(Under the direction of A. Gregory Matera) 
 
Spinal Muscular Atrophy (SMA) is a common neuromuscular disease that affects 
one in 6,000-8,000 young children; most of whom die before reaching the age of two 
years. One in fifty Americans is a carrier for SMA, making this genetic disease a serious 
health concern. More than 95% of patients with SMA carry deletions in the survival 
motor neuron 1 (SMN1) gene. The SMN protein is essential for survival and has a well-
characterized role in the biogenesis of small nuclear ribonucleoproteins (snRNPs), which 
are core components of the spliceosome. Numerous additional functions, both 
housekeeping and tissue-specific, have been put forth in the literature, however, no 
convincing link has been made between any putative SMN function and the disease 
etiology. 
To address this question, we are studying the consequences of SMN loss in the 
Drosophila model system. We have generated a series of transgenic flies that exclusively 
express mutant forms of SMN derived from human SMA patients to uncouple the 
housekeeping and tissue-specific functions of SMN. Null mutants in Smn die as larvae, 
show significant motility defects, and have reduced levels of minor-class snRNAs.  
Surprisingly, despite these reductions, minor-class intron splicing in these mutants is 
unperturbed. In addition, we find that rescue of the null mutant with a WT SMN 
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construct does not restore snRNA levels, but does rescue the motility defects and lethality 
of the Smn null flies.  In addition, the majority of flies expressing an SMA point 
mutation, T205I, die as pupae but have a similar snRNA profile to the WT transgenic 
animals. These data suggest that the reduction in snRNAs in Smn mutants is not a major 
contributor to their lethality, and indicate that non-snRNP related functions of SMN may 
be critical to SMA pathology. We have generated twelve additional point mutations in 
Smn that mimic mutations identified in SMA patients. The phenotypes of these mutations 
reflect the range of severities seen in SMA patients, and will be important tools in 
identifying the functions of SMN that form the etiological basis for SMA.  
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 CHAPTER I  
Introduction 
Spinal Muscular Atrophy 
Proximal spinal muscular atrophy, also called spinal muscular atrophy (SMA), is 
the most prevalent genetic cause of infant mortality.  With a carrier frequency of 1 in 50 
and an incidence rate of 1 in 6000-10,000, it is also the most common autosomal 
recessive disorder in the population after Cystic Fibrosis (Ogino et al., 2002).  The 
disease is characterized by the degeneration of motor neurons in the anterior horn of the 
lower spinal cord, leading to symmetrical paralysis, atrophy of the proximal muscles, and 
loss of motor function.  SMA can be classified into three types based on the severity of 
the phenotype, which is determined by the age of onset and the level of maximum motor 
function achieved by the patient (Ogino S, 2004).  Type I SMA, also known as Werdnig-
Hoffman disease, is the most severe form where symptoms can be apparent as early as in 
utero. Affected infants experience progressive muscle weakness and hypotonia (reduced 
muscle tone), accompanied by a reduced ability to swallow and die from complications 
such as respiratory failure by 2 years of age.  Type II SMA is less severe with symptoms 
occurring between 6 and 18 months of age.  These children experience developmental 
motor delays and although able to sit unsupported, they are unable to stand or walk.  The 
expected lifespan of type II patients can vary from 2 to 30 years, with death usually 
occurring as a result of respiratory infections.  SMA type III is the mildest form with an 
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age of onset after 2 years.  Most type III patients are able to stand and walk, but can 
become wheelchair bound in adulthood.  The disease progress is slow and many type III 
patients have a normal life expectancy.   Type I SMA is the most common form of the 
disease, affecting ~60% of SMA patients (Nicole et al., 2002; Ogino S, 2004).  
SMA Etiology 
In 1990, linkage analysis was used to map the SMA causing gene to chromosome 
5q11.2-13.3 in several SMA affected families (Brzustowicz et al., 1990; Melki et al., 
1990).  Five years later, Lefebvre et al. (1995) identified a novel gene that lies in the 
critical region, survival of motor neuron 1 (SMN1), as the causative gene in SMA 
(Bussaglia et al., 1995; Rodrigues et al., 1995; van der Steege et al., 1995; Chang et al., 
1997).  SMN1 produces a 1,536 bp mRNA from 9 exons that code for a 294 amino acid 
protein.  Over 95% of SMA patients have deletions involving exon 7 of SMN1 (Lefebvre 
et al., 1995; Campbell et al., 1997).      
Further characterization of the 5q region revealed the existence of at least two 
copies of the SMN gene in most people. The telomere-proximal copy (SMN1) and the 
centromere-proximal copy (SMN2) arose as a result of a 500 kb inverted duplication 
located at 5q11-13 (Lefebvre et al., 1995).  There are five base pair differences that 
distinguish the two SMN copies at the nucleotide level, but they leave the sequence of the 
protein unchanged. One of these is a change from C to T in exon 7 of the SMN2 gene, 
which results in the exclusion of exon 7 (SMN∆7) in ~90% of the SMN2 transcripts 
(Lorson et al., 2010) (Fig. 1.1).  This “SMN∆7 transcript” encodes a truncated and 
unstable protein.  The remaining ~10% of transcripts are full length, and encode protein 
 that is functional and indistinguishable from that produced by 
Monani et al., 1999; Lorson et al., 
 
  
Figure 1.1. SMN2 cannot fully compensate for loss of 
in the SMN2 gene results in the exclusion of exon 7 and production of a truncated and 
unstable protein ~90% of the time. 
 
Studies in SMA patients 
of the phenotype and the amount
1997). These findings, coupled with the existence of two non
humans, led to the formulation of a gene
SMA is now thought to be a gene dosag
phenotype.  There is an inverse correlation between the number of 
genome and disease severity. Mildly affected patients generally have more copies of 
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SMN1 (Lorson et al., 1999
2000). 
SMN1. A base change from C to T 
 
have revealed an inverse correlation between the severity 
 of functional, full length SMN protein (Lefebvre et al., 
-redundant SMN
-disease relationship between SMN and SMA.  




 paralogs in 
copies in the 
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SMN2 than patients with more severe phenotypes (Vitali et al., 1999). Consistent with 
this observation, earlier studies had found that the levels of SMN protein in cells from 
SMA type I patients were reduced to 5-20% of levels in controls, while in type III SMA 
patients, SMN levels were comparable to controls (Lefebvre et al., 1997; Vitali et al., 
1999). It is hypothesized that type I SMA is caused by deletions and/or mutations in the 
SMN1 gene, whereas type III SMA generally results from gene conversion events that 
convert SMN1 to SMN2 (Campbell et al., 1997).  In the latter case, there are more copies 
of SMN2 and thus more functional SMN protein, resulting in a milder SMA phenotype. 
Missense mutations in SMN1 have also been identified in SMA patients in all three 
categories of SMA, however, these are rare compared to gross deletions of the gene 
(Burghes et al., 2009).          
SMN Function 
Clues to the function of SMN first came from observations that the protein can 
associate with the RNA binding domain of hnRNP U, an RNA binding protein. This 
suggested that SMN has roles in RNA metabolism (Liu et al., 1996).  In 1997, Liu et al. 
showed that SMN, along with Gemin2 (previously called SMN interacting protein I 
(SIP1)), co-purified with a set of proteins that bind to uridine-rich small nuclear 
ribonucleoproteins (U-snRNPs), named Sm proteins.  In the same year, Fischer et al. 
(1997) used Xenopus oocytes to show that SMN and Gemin2 were involved in an early 
step in spliceosomal U-snRNP biogenesis. These data were corroborated in 2001 by 
Meister et al., who showed more definitively that SMN and Gemin2, along with a 
number of other proteins now referred to as the ‘SMN complex’, were required for the in 
vivo assembly of Sm proteins onto U-snRNAs.  
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snRNP biogenesis 
Uridine-rich snRNAs are non-coding RNAs that perform diverse cellular 
functions (Kiss, 2004). In particular, the Sm-class U-snRNAs that are assembled by the 
SMN complex form core components of the spliceosome. Eukaryotic genomes encode 
RNAs that form two distinct spliceosomes. The so-called “major” spliceosome, is 
responsible for splicing of over 99% of introns in the human genome, whereas the 
“minor” spliceosome catalyzes removal of the remaining <1% of introns (Levine et al., 
2001). The major spliceosome is comprised of the snRNAs U1, U2, U4 and U6, which 
are referred to as major-class snRNAs. The minor spliceosome is formed by the minor-
class snRNAs U11, U12, U4atac and U6atac. Another spliceosomal snRNA, U5, is a 
component of both spliceosomes (Patel et al., 2003). Consistent with a greater 
requirement for the major spliceosome, the major-class snRNAs are ~100 fold more 
abundant than the minor-class snRNAs (Zieve et al., 1990). 
The life cycle of the Sm-class U-snRNAs, U1, U2, U4, U11, U12 and U5, is 
biphasic (Fig. 1.2), involving nuclear and cytoplasmic maturation steps. Sm-class U-
snRNAs are transcribed by RNA polymerase II and acquire a 7-methylguanosine (m7G) 
cap (Cougot et al., 2004). Following transcription and 3' end processing, the pre-snRNA 
is bound by the cap binding complex (CBC) (Izaurralde et al., 1995). The pre-snRNA 
then transits through nuclear structures called Cajal Bodies (CBs), where it is recognized 
by the phosphorylated adaptor for RNA export (PHAX) (Frey et al., 1995; Frey et al., 
1999; Ohno et al., 2000; Frey et al., 2001; Suzuki et al., 2010). PHAX recruits 
CRM1/RanGTP to the pre-snRNA, and this complex is exported to the cytoplasm. The 
pre-snRNA is released upon phosphorylation of PHAX in the cytoplasm (Ohno et al., 
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2000).  The SMN complex then facilitates the binding of seven proteins, SmB/B’, SmD1, 
SmD2, SmD3, SmE, SmF and SmG (the Sm proteins), onto a conserved motif called the 
‘Sm site’ on the pre-snRNA (Meister et al., 2001a; Yong et al., 2002; Yong et al., 2004; 
Golembe et al., 2005) in an adenosine triphosphate (ATP) dependent reaction. The SMN 
complex provides specificity and speed to this reaction, which can also occur 
spontaneously and non-specifically in vitro (Pellizzoni et al., 2002b). Another complex 
called the protein arginine methyltransferase 5 (PRMT5) complex, consisting of PRMT5, 
pICln and WD45 (Mep50), symmetrically dimethylates SmB, SmD1 and SmD3 on their 
RG rich C-terminal domains (Brahms et al., 2000; Brahms et al., 2001; Friesen et al., 
2001; Meister et al., 2001b; Friesen et al., 2002). This methylation enhances the binding 
between these Sm proteins and SMN, and is thought to be important for the transfer of 
Sm proteins onto snRNAs. However, in Drosophila, the Sm protein methylation activity 
carried out by the PRMT5 ortholog, Dart5, is not necessary for the snRNP assembly 
process (Gonsalvez et al., 2008).    
After assembly with Sm proteins, the pre-snRNA is trimmed at the 3’ end 
(Kleinschmidt et al., 1987; Seipelt et al., 1999; Will et al., 2001) and the m7G cap is 
hypermethylated to a trimethylguanosine (m3G) cap by the enzyme TGS1 (Mattaj, 1986; 
Huang et al., 1999; Mouaikel et al., 2002). SMN and TGS1 are thought to physically 
interact suggesting a role for SMN in TGS1 recruitment or function (Mouaikel et al., 
2003).  The import adaptor, Snurportin (SPN), and Importinβ (Impβ) take the partially 
assembled pre-snRNA, and the SMN complex, into the nucleus (Palacios et al., 1997; 
Huber et al., 1998; Narayanan et al., 2004).  Interaction between SMN and Impβ, and 
observations that snRNP import is defective in the presence of some SMN mutations, 
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indicate that SMN may also function in facilitating snRNA import (Narayanan et al., 
2002; Narayanan et al., 2004).  In the nucleus, the snRNA localizes to CBs, where it is 
released from the SMN complex, modified, and bound by other snRNP-specific proteins. 
The mature snRNP then localizes to either regions of active transcription and splicing 
(perichromatin fibrils) (Fakan, 1994) or to nuclear domains called speckles, where 




Figure 1.2. Illustration of the major steps in 
After transcription by RNA polymerase II, 3’
and being bound by the cap binding complex (CBC) the pre
en route to the Cajal body (CB). PHAX then recruits CRM1 and Ran to export the pre
snRNA out to the cytoplasm. In the cytoplasm, PHAX,
from the pre-snRNA, which gets loaded with a seven
the SMN complex. A subset of Sm proteins are thought to be symmetrically methylated 
by the PRMT5 complex to facilitate their recognition by SM
pre-snRNA. The pre-snRNA is further modified by methylation of the 7
guanosine (m7G) cap to a trimethylguanosine (m
the snRNA by an exonulcease (EXO)
with the SMN complex by Snurportin (SPN) and Importin
the CB. In the CB, the snRNA 
before localizing to speckles for storage or to 
 
The two spliceosomal snRNAs, U6 and U6atac, do not follow the same assembly 
pathway as the others.  U6 and U6atac are RNA polymerase III transcripts that acquire a 
8
the mammalian snRNP biogenesis pathway
 end processing by the integrator complex 
-snRNA is bound by PHAX 
 CRM1, Ran and the CBC release 
 membered ring of Sm proteins by 
N and their transfer onto the 
3G) cap and trimming of the 3’
. The snRNA is imported into the nucleus along 
β (Impβ), where it localizes to 
binds other proteins and acquires further modifications 





 end of 
.   
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γ-monomethyl cap after transcription. They are then bound by seven Sm-like (Lsm) 
proteins (Lsm2-Lsm8) (Achsel et al., 1999), and are referred to as “Lsm-class” snRNAs. 
Their assembly is thought to occur entirely within the nucleus, and appears to be 
independent of SMN.  
snRNP independent functions of SMN 
While snRNP biogenesis remains by far the most well established function of 
SMN, the protein has also been implicated in other global and tissue-specific roles in the 
cell (Fig. 1.3). SMN is reported to interact with and influence the activity of E2, a viral 
transcription activator (Strasswimmer et al., 1999), as well as with RNA helicase A and 
RNA polymerase II (Pellizzoni et al., 2001), invoking the possibility that it may function 
in transcriptional regulation.  
A number of observations have raised the possibility of neuron and muscle 
specific roles for SMN. The localization of SMN to growth cones in differentiating PC12 
and P19 cells (Fan et al., 2002; Sharma et al., 2005) along with defects in axonal growth 
of motoneurons in mouse and zebrafish models of SMA (McWhorter et al., 2003; Rossoll 
et al., 2003) indicate a possible function for SMN in neurite outgrowth and axonal 
pathfinding.  A model of SMN function in mRNP transport along motoneuron axons has 
emerged from studies that showed defects in localization of β-actin mRNA in developing 
motoneurons of SMA mice (Rossoll et al., 2003).  SMN has also been implicated in 
neuromuscular junction (NMJ) formation (Fan et al., 2002; Chan et al., 2003; Kariya et 
al., 2008), and in regulating actin dynamics via SMN’s ability to interact with Profilin 
and Plastin3 (Giesemann et al., 1999; Sharma et al., 2005).  Compelling evidence for a 
muscle specific function of SMN has been shown.  Mouse C2C12 cells, which can be 
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induced to differentiate into muscle fibers, were used to show that reduced levels of SMN 
resulted in myoblast fusion defects and morphologically abnormal myotubes (Shafey et 
al., 2005). The severity of these defects was proportional to the level of SMN expression. 
Rajendra et al. (2007) also observed localization of SMN to sarcomeres (the contractile 
units of muscle fibers) in Drosophila and in mice.  They demonstrated a severe 
disorganization of the flight muscles in an adult Drosophila model of SMA, suggesting a 




Figure 1.3. A summary of the different functions ascribed to S
neuronal cell body where the SMN complex is involved in assembly of 
spliceosomal snRNPs. SMN has also been 
along the neuronal axon, in axonal growth, in neuromuscular junction formati
myoblast fusion and maintenance of muscle architecture. Figure 
of Karl Shpargel (Shpargel, 2006
 
SMN protein and the SMN complex
The SMN1 gene and protein are highly conserved in evolution, with homologs in 
all major eukaryotic model organisms investigated except 
primates are the only species that have 
Furthermore, only humans have the 
determined by the inability to detect any 
chimpanzee (DiDonato et al., 1997
294 amino acids long and has two well described domains:
found in many RNA-binding proteins, 
Tudor domain is thought to be involved
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; Rochette et al., 2001).  The human SMN prote
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and a region called the YG box (Fig.
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 1999) and the YG box has been characterized as a 
most well conserved region 
reported some self-association activity at the N
Gemin2 binding site (Young et al., 2000
 
Figure 1.4. Major domains in the SMN protein. The SMN protein has an N
domain that is important for binding to Gemin2. This region may also contribute to the 
self-association of SMN. The 
proteins, interacts with Sm proteins, and the YG box mediates SMN oligomerization. 
 
Consistent with its function in the housekeeping process of snRNP biogenesis, 
SMN is ubiquitously express
the cytoplasm as well as in the cell
whereas in the nuclei of most tissues 
(Carvalho et al., 1999).  CBs
silver chromate staining (SRy, 1903
nucleolar ribonucleoproteins (snoRNPs), small 
(scaRNPs) as well as other proteins involved in RNP metabolism
al., 2006).  The marker used in 
localizes specifically to these structures 
Studies over the last decade have shown that SMN is
multimeric complex consisting of eight additional proteins
12
self-oligomerization domain and is the 
in the protein (Lorson et al., 1998). Two studies have also 
-terminal end of SMN, overlapping the 
; Ogawa et al., 2007). 
tudor domain, which is present in many RNA binding 
ed (Coovert et al., 1997; Burlet et al., 1998), and localizes 
 nucleus.  In the cytoplasm, the SMN signal is diffuse
it is concentrated in foci corresponding to 
 are nuclear structures initially characterized by their intense 
).  They contain high levels of snRNPs, small 
Cajal body specific ribonucleoproteins 
 (reviewed in 
more recent times for CBs is the protein coilin, which 
(Andrade et al., 1991). 
 found as part of a large 








 Gemin5, Gemin6, Gemin7, Gemin8 and Unrip
(Charroux et al., 1999; Charroux et al., 2000
Pellizzoni et al., 2002a; Grimmler et al., 2005
Importantly, the SMN complex, as a whole, is required for snRNP assembly.  Addition of 
SMN and Gemin2 alone were not sufficient to restore RNP assembly activity in 
egg extracts immunodepleted for these proteins 
studies have further confirmed this requirement for the other members of the SMN 
complex in snRNP assembly
2005; Battle et al., 2006; Ogawa et al., 2007
complex members may also be involved in snRNP















Figure 1.5. Cartoon depiction of the cytoplasmic mammalian SMN complex
numbered ovals in the complex represent Gemins2
contacts with SMN. Only one subunit of the oligomeric SMN complex is depicted here. 
Based on Otter et al., 2007. 
   
While orthologs of Gemin2 can be identified in all species investigated, the other 
Gemins are not as well conserved. A comprehensive bioinformatic investigation to 
13
 (a cytoplasm specific complex member
; Baccon et al., 2002; Gubitz et al., 2002
; Carissimi et al., 2006
(Meister et al., 2001a). A number of 
 (Meister et al., 2001a; Feng et al., 2005; Shpargel et al., 
). Additionally, it appears that the SMN 
-independent functions in which SMN 
; Walker et al., 2008; Todd et al., 2010
-8. Gemins2, 3, 7 and 8 make direct 
     
) 
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identify Gemin homologs showed that Gemins 5 and 3 are the most ancestral Gemins in 
the complex (Kroiss et al., 2008). Putative homologs of Gemins 6, 7, 8 and 4 were only 
found in metazoans, suggesting that they are newer additions to the complex. 
Interestingly, both Dipterans that were analyzed (D.melanogaster and A.gambiae) seem 
to have only Gemins 2, 3 and 5.  
In particular, Gemins 2, 3, 4 and 5 are required, in addition to SMN, for snRNP 
assembly in HeLa cells (Feng et al., 2005; Shpargel et al., 2005). However, it was 
recently shown in vitro that a minimal SMN complex, consisting of SMN and Gemin2 
only, was sufficient for assembly of Sm proteins onto snRNAs (Kroiss et al, 2008). This 
finding suggests that while the other SMN complex members may not be essential for the 
assembly reaction per se, they play ‘supportive’ roles to enhance snRNP assembly in 
vivo. It is known that the SMN complex is associated with the Sm-snRNA complex 
throughout the cytoplasmic phase of assembly (Massenet et al., 2002) and is also 
important for re-import of the immature snRNP into the nucleus (Narayanan et al., 2002; 
Narayanan et al., 2004). Hence, it is possible that the Gemins have critical functions in 
steps downstream to the assembly of Sm proteins onto snRNAs. Notably, although 
Drosophila seems to lack many of the components of the SMN complex, its genome does 
contain orthologs for most of the Gemins that are known to be important for snRNP 
biogenesis in vivo.    
Naming the SMN complex members as ‘Gemins’ can be confusing as it tends to 
give the impression that these proteins share functional or structural similarity. In fact, 
the Gemins are structurally very different to each other. The precise function of most of 
the Gemins in the SMN complex is not clear. Gemin5 has been shown to bind snRNAs 
 15
directly, and is implicated in distinguishing them from other RNAs, thus, providing 
specificity to the assembly reaction (Battle et al., 2006). Gemin2 has been reported to 
help stabilize SMN by enhancing SMN’s N-terminal domain mediated self-association 
(Ogawa et al., 2007). Recently, a crystal structure of Gemin2 with the Gemin2-binding 
domain of SMN revealed that Gemin2 bound a pentamer of the Sm proteins D1, D2, E, F 
and G directly (Zhang et al., 2011). Gemins 6 and 7 form a heterodimer that resembles 
the structure created by heterodimers of SmB/SmD3 and SmD1/SmD2 (Ma et al., 2005), 
and also to interact with a subset of Sm proteins. Thus, it has been proposed that Gemins 
6 and 7 may act as “place holders” for SmB/SmD3 in the Sm protein pentamer that binds 
Gemin2 (Zhang et al., 2011) before assembly onto the snRNA. Gemin3 is a DEAD box 
domain containing protein with potential helicase activity, and may perform the ATP 
dependent step of the assembly reaction (Charroux et al., 1999). No functions have been 
assigned to the remaining members of the SMN complex.  
Modeling SMA in Drosophila 
Integral aspects of cell and developmental biology in humans have been 
conserved in Drosophila.  Approximately 75% of disease-causing loci in humans have 
homologs in the fly (Reiter et al., 2001).  This conservation allows us to model and study 
human disorders in an organism that is likely to respond with similar pathology to disease 
causing mutations. Furthermore, the availability of a sequenced genome, several genetic 
tools and a short generation time make the fruitfly a particularly attractive model 
organism. Neuromuscular development in adult flies resembles that of vertebrates, thus 
making Drosophila suited for study of disorders such as SMA (Fernandes et al., 1999). 
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The Drosophila Smn ortholog is an 828 nucleotide, intron-less gene that codes for 
a 226 amino acid protein (dSMN).  The human and fly homologs share 23.5% identity 
and 36.7% similarity.  The regions showing greatest conservation correspond to the 
Gemin2 binding site near the N-terminus, the Tudor domain and the YG box (Miguel-
Aliaga et al., 2000).  The Drosophila SMN complex participates in the assembly of Sm 
proteins onto snRNAs, indicating that the function of human SMN in snRNP biogenesis 
is conserved in the fly (Rajendra et al., 2007). 
Drosophila SMA models 
Chan et al (2003) isolated two point mutations in the YG (self-oligomerization) 
box of dSMN through a small-scale ethyl methane sulphonate (EMS) mutagenesis screen.  
Mutant animals survived only until the late larval stages and showed increasing loss of 
mobility and coordination.  Using genetic mosaic techniques to create homozygous SMN 
mutants specifically in the germ line of female flies, the authors showed that survival of 
zygotic SMN mutants beyond embryogenesis was due to a large maternal contribution of 
SMN. Several Smn mutants are available that have been generated via transposon 
mediated mutagenesis (Rajendra et al., 2007; Shpargel et al., 2009) (Fig. 1.6). These vary 
in the severity of their phenotype based on the location of the insertion. Recently, a 
deletion that removes the promoter, open reading frame and part of the 3` UTR of SMN, 
called SmnX7, was generated from a parent line carrying a transposon insertion upstream 
of the gene, SmnE (Chang et al., 2008). These fly models of SMA are useful for the study 
of larval phenotypes but not adult phenotypes.  In addition, these models do not 
recapitulate human SMA, which is caused by a reduction, but not complete loss, of 
functional protein.   
  
Figure 1.6. Mutations in the 
with gray boxes on either side representing 3` and 5` UTRs
insertions are shown as black triangles. 
+407 bp (coding region) and 
SmnE is a P-element insertion upstream of the transcription start site at 
an imprecise excision mutation derived from 
from excision of SmnE33. This deletion 
start site, the whole of the 5` UTR, coding region and the 5` most 45 bases of the 3` UTR 
of Smn. SmnA and SmnB are both point mutations in the oligomerization domain (YG box) 
of Smn.  
 
Previously, our lab generated
addresses the aforementioned issues. 
imprecise excision of a P element insertion located upstream to the 
for adult flies with neuromusc
(excision 33), are viable and fertile, but unable to fly or jump.  Severe atrophy of the 
flight muscles was observed in the mutants, indicated by 
the flight muscles.  This was accompanied by routing and branching defects in the dorsal 
longitudinal motor neurons of the flight muscles
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Other animal models of SMA 
SMA has also been modeled in mice, fish, worms and fission yeast (Miguel-
Aliaga et al., 1999; Hsieh-Li et al., 2000; Monani et al., 2000a; Owen et al., 2000; 
McWhorter et al., 2003). Severe reduction or complete knockout of Smn in these 
organisms is lethal. Moderate reductions in SMN levels in C.elegans and zebrafish, 
resulted in uncoordination, paralysis and lack of muscle tone in the former, and motor 
axon pathfinding defects in the latter (without any defects in muscles or overt movement 
defects). To achieve a milder reduction in SMN levels and thus obtain a mouse model 
that more closely resembled the human disorder, two groups generated mice that 
expressed the human SMN2 gene in the background of a homozygous mouse Smn 
mutation (Smn-/-; SMN2) (Hsieh-Li et al., 2000; Monani et al., 2000b). This model 
rescued the embryonic lethality of Smn-/- mice and recapitulated many of the 
pathological features seen in SMA patients. These include a much shorter lifespan, 
degeneration of spinal motor neurons and progressive muscle weakness (Monani et al, 
2000).  Furthermore, similar to the human disease, varying the number of copies of 
SMN2 varied the severity of the phenotype from that resembling type I (1 or 2 copies) 
patients to types II and III, and complete rescue (8-10 copies).  
The conundrum of SMA pathology 
The central question facing researchers in the SMA field is how the loss of a 
protein with an essential and ubiquitous function can cause a primarily neuromuscular 
disease. Current hypotheses suggest that certain tissues, such as neurons or muscles, may 
have a greater requirement for snRNPs thus making them more susceptible to defects in 
 19
snRNP biogenesis, or that disruptions to the tissue-specific functions of SMN lead to 
SMA. These hypotheses need not be mutually exclusive.  
SMA and snRNP biogenesis 
Several groups have attempted to find a correlation between snRNA levels in 
SMA models and the disease phenotype. The results appear to be conflicting. Studies in 
mouse models of SMA showed a decrease in the levels of some minor-class spliceosomal 
snRNAs in homozygous mutant mice compared to heterozygous littermates (Gabanella et 
al., 2007; Zhang et al., 2008). This decrease varied tissue-specifically in both the degree 
of reduction as well as the type of snRNA affected (Zhang et al, 2008).  Fibroblasts from 
SMA patients, however, did not show any change in snRNA levels despite a severe 
reduction in Sm protein assembly activity in vitro (Gabanella et al, 2007). One study in 
zebrafish failed to find a correlation between snRNP assembly competency of select 
SMA-causing point mutations and resulting severity of motor neuron defects (Carrel et 
al., 2006). However, another study in mice found a positive correlation between snRNA 
levels and severity of the phenotype of SMA-causing mutations (Workman et al., 2009).  
To understand the functional consequence of snRNA level defects, Zhang et al 
(2008) used exon microarrays to assay splicing changes on a genome-wide scale in a 
mouse SMA model. They reported widespread splicing changes in these mice, however, 
a subsequent study showed that the vast majority of these changes were characteristic of 
late stages of SMA (Baumer et al., 2009). Thus, they are likely to be a consequence of 
disease progression rather than the cause. Additionally, a deficiency in the assembly of 
the minor-class tri-snRNP (made up of U4atac, U6atac and U5) was also observed in 
SMA patient lymphoblasts (Boulisfane et al., 2011). Despite this defect, the splicing of 
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90% of minor-class intron containing genes that were tested was unaffected in these cells. 
Collectively, these studies do not establish a convincing link between snRNP biogenesis 
defects and SMA pathophysiology.   
Compelling observations support the idea of a snRNP-independent pathology for 
SMA. Rajendra et al (2007) described a possible muscle-centric function of SMN, which 
does not involve snRNPs, in a SMN hypomorphic fly that showed flight muscle defects.  
This phenotype resembles flies with mutations in Act88f, a muscle specific actin, 
implicating defects in actin-dynamics in the pathology of the SMN hypomorphic flies. 
The involvement of actin-dynamics in SMA has also been suggested by identification of 
Plastin3 (an actin bundling protein) as a modifier of type III SMA in humans (Oprea et 
al., 2008); and by mouse studies that show a disruption to the levels of profilin IIA and 
plastin3 upon SMN reduction (Bowerman et al., 2007; Bowerman et al., 2009). 
Previously, Shpargel and Matera (2005) analyzed eight SMA-patient derived point 
mutations in the human SMN protein for their activities in an in vitro snRNP assembly 
assay.  Three of these mutations did not show significant reduction in RNP assembly.  
These studies suggest the existence of snRNP independent functions of SMN that are 
relevant to the pathology of SMA. 
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Research Objectives 
Spinal muscular atrophy is a neuromuscular disorder caused by mutations in the 
SMN protein. The best characterized function of SMN is in the biogenesis of snRNPs, 
core components of the spliceosome. The mechanism of SMA disease pathology has 
remained enigmatic, primarily hinging on the reconciliation of the neuromuscular (tissue-
specific) nature of the disorder with the ubiquitous and essential function of SMN. My 
approach to elucidate critical functions of SMN in SMA is by selectively disrupting 
subsets of SMN functions and analyzing their effects. As the extant Drosophila models of 
SMA are null mutants that affect all functions of SMN, to do this, I decided to create new 
models of SMA based on point mutations identified in SMA patients. I have analyzed 
these mutations on an organismal level as well as on a molecular level to decipher how 
they affect the interactions/functions of dSMN. I also compared and contrasted these 
mutations to the phenotype of null mutants in Drosophila Smn.   
 CHAPTER II 
A Drosophila model of Spinal Muscular Atrophy uncouples the snRNP 
biogenesis functions of survival motor neuron from locomotion  
and viability defects 
Introduction 
Spinal muscular atrophy (SMA) is the most prevalent genetic cause of early 
childhood mortality, resulting from recessive loss-of-function mutations in the survival 
motor neuron 1 (SMN1) gene (Lefebvre et al., 1995). The disease is characterized by 
degeneration of motor neurons in the anterior horn of the lower spinal cord, leading to 
progressive symmetrical paralysis, accompanied by atrophy of the proximal muscles and 
loss of motor function (Crawford et al., 1996). SMA symptoms vary in severity, and are 
classified by types I to IV, ranked in decreasing order (Ogino et al., 2004). In the most 
severe form of the disease (type I), which is also the most common, death usually occurs 
by 2 years of age. 
SMN is the central component of a multimeric protein assemblage known as the 
SMN complex (Burghes et al., 2009). The best characterized function of this complex is 
in the biogenesis of small nuclear ribonucleoproteins (snRNPs), primary components of 
the spliceosome. The SMN complex chaperones assembly of core RNA-binding factors 
called Sm proteins onto non-coding, Sm-class spliceosomal snRNAs (Meister et al., 
2001a; Pellizzoni et al., 2002b). Complete loss of SMN is lethal in all organisms 
investigated to date (Monani, 2005). SMA, therefore, is a disease that arises due to a 
reduction in SMN levels, not a complete loss. Humans have two paralogs of SMN, 
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named SMN1 and SMN2, both of which contribute to the total cellular levels of SMN 
protein. SMN2, however, contains a single base change that primarily leads to production 
of a truncated, unstable protein product (Lorson et al., 1999). Current estimates suggest 
that SMN2 produces only 10-15% of the level of full-length protein produced by SMN1 
(Lorson et al., 2010). Whilst this amount is not enough to completely compensate for loss 
of SMN1, SMN2 is sufficient to rescue embryonic lethality (Monani et al., 2000b). 
A causative link between SMN1 and SMA was established over 15 years ago, 
however, the mechanism of disease pathology remains unclear. A causative link between 
SMN1 and SMA was established over 15 years ago, however, the mechanism of disease 
pathology remains unclear. In addition to roles in snRNP biogenesis, SMN has been 
implicated in a number of tissue-specific processes, including: axonal pathfinding (Fan et 
al., 2002; McWhorter et al., 2003; Sharma et al., 2005), axonal transport of β-actin 
mRNP (Rossoll et al., 2003), neuromuscular junction formation and function (Chan et al., 
2003; Kariya et al., 2008; Kong et al., 2009; Voigt et al., 2010), myoblast fusion (Shafey 
et al., 2005) and maintenance of muscle architecture (Rajendra et al., 2007; Walker et al., 
2008; Bowerman et al., 2009). Thus it is not surprising that therapeutic approaches 
targeting SMA are primarily focused on increasing production of full-length SMN 
protein from the SMN2 gene in patients (Lorson et al., 2010). While these approaches are 
extremely important, it is clear that a deeper understanding of the molecular etiology of 
SMA will be essential to develop effective treatments and minimize side-effects. 
Here, we present a new Drosophila model system to study SMA patient-derived 
loss-of-function mutations in the background of an Smn null allele. Smn null mutants 
display a modest reduction in the levels of a subset of snRNAs and considerable defects 
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in larval locomotion. Transgenic expression of FLAG-tagged wild-type (WT) dSMN 
rescues larval locomotion and organismal viability but, surprisingly, fails to rescue 
snRNA levels. Expression of an SmnT205I construct (which mimics SMNT274I in humans) 
also rescues the larval motility and viability defects, but the majority of these animals die 
as pupae with an snRNA profile similar to that of the wild-type transgenics. These data 
show that the observed decreases in snRNA levels in Smn null animals are not major 
contributors to organismal phenotype, and indicate that non-snRNP biogenesis functions 
of SMN play important roles in SMA pathology. 
Experimental Procedures 
Fly stocks and genetics 
Oregon-R was used as the wild-type allele. The SmnX7 microdeletion allele 
(Chang et al., 2008) was a gift from S. Artavanis-Tsakonis (Harvard University, 
Cambridge, USA). The SmnD (f01109) transposon insertion allele was obtained from the 
Exelixis collection at Harvard Medical School and isogenized to remove non-Smn flies 
contaminating this stock (Rajendra et al., 2007). Other fly lines were obtained from the 
Bloomington Stock Center.  All stocks were cultured on molasses and agar at room 
temperature (24 ± 1°C) in half-pint bottles. The WT and T205I transgene constructs were 
injected into embryos by BestGene Inc. (Chino Hills, CA). To rescue the Smn null 
phenotype, the WT and T205I transgenic lines were recombined with the SmnD line. 
Recombinants were identified by genotyping, verified by western analysis for FLAG-
dSMN expression and subsequently crossed with SmnX7 for analysis. 
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Rescue constructs 
A ~3kb fragment containing the entire Smn coding region was cloned from the 
Drosophila genome into the pAttB vector (Bischof et al., 2007). A 3X FLAG tag was 
inserted downstream of the start codon of dSMN. The T205I point mutation was 
introduced into this construct using Quickchange (Invitrogen) site-directed mutagenesis 
according to manufacturer’s instructions. 
Antibodies and Western blotting 
Larval, pupal and adult lysates were prepared by crushing the animals in lysis 
buffer (50mM Tris-HCl, pH 7.5, 150 mM NaCl, 1mM EDTA, 1% NP-40) with 1X 
protease inhibitor cocktail (Invitrogen) and clearing the lysate by centrifugation at 13,000 
RPM for 10 min at 4ºC. Western blotting on lysates was performed using standard 
protocols. Rabbit anti-dSMN serum was generated by injecting rabbits with purified full-
length dSMN protein (Pacific Immunology Corp, CA), and was subsequently affinity 
purified. For Western blotting, dilutions of 1 in 2,500 for the affinity purified anti-dSMN, 
1 in 10,000 for anti-α tubulin (Sigma) and 1 in 10,000 for polyclonal anti-Myc (Santa 
Cruz) were used. Anti-FLAG antibody crosslinked to agarose beads (EZview Red Anti-
FLAG M2 affinity gel, Sigma) was used to immunoprecipitate FLAG tagged proteins 
from cells. 
Northern blotting 
Larvae, pupae and adult Drosophila were homogenized in TRIZOL (Invitrogen) 
and total RNA was extracted following manufacturer’s instructions. RNA was run on a 
standard 10% polyacrylamide-urea gel (Invitrogen), transferred to a nylon membrane, 
and probed with 32P-labeled PCR products corresponding to the D. melanogaster U1, U2, 
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U4, U5, U6, U11, U12, U4atac, U6atac, and 7SK cDNAs. The blots were visualized 
using a Typhoon phosphorimager (Molecular Dynamics) and quantification was 
performed by densitometry using ImageQuant software. 
Larval motility assays 
Larvae used for the motility assays were ~76 hours old. For the righting assay, 
larvae were placed on a 3% agarose plate for 120 sec to allow them to equilibrate to the 
new environment. They were then placed on their ventral surfaces and the time taken to 
return to a crawling position was noted. The assay was terminated at 120 sec. For the 
burrowing assay, thirty larvae were placed on a molasses plate with 1.5% agarose. The 
plates were kept in the dark and the number of larvae remaining on the surface was 
counted after 2 hours. Statistical significance for the righting and burrowing assays were 
determined using the Student’s T-test and chi-squared test, respectively. 
Real-time PCR 
One microgram of total RNA from ~76 hour larvae was used in a 20µl reverse 
transcriptase reaction with random hexamer primers (Superscript III first strand synthesis 
system, Invitrogen), and ~50-100ng of the cDNA was used for qRT-PCR. Real-time PCR 
reactions were carried out on an Applied Biosystems 7900HT Fast Real-time PCR 
machine using Maxima® SYBR Green/Rox qPCR master mix (Fermentas). Three 
technical replicates were run for each reaction and three biological replicates were tested 





Characterization of Smn null flies 
In order to minimize genetic background effects arising from recessive second-
site mutations, we used flies bearing two different Smn null alleles for phenotypic 
characterization. SmnD/+ flies were crossed with SmnX7/+ to produce SmnD/X7 trans-
heterozygous flies (Rajendra et al., 2010), herein referred to as Smn-/-. Smn-/- larvae begin 
to die in early third instar, ~80 hrs (day 4) post egg laying (Fig. 2.1A). The primary lethal 
phase continues through day 5, after which time the number of larvae reduces gradually. 
Consistent with previous observations (Shpargel et al., 2009), 20-30% of Smn null larvae 
are ‘long lived’ and survive for several more days without undergoing metamorphosis or 
exhibiting the wandering behavior typical of the late third instar. Larval dSMN levels are 
highest at 1 day post egg laying (DPE), then decrease and remain constant. In Smn-/- 
mutants, dSMN levels are already reduced on day 1 and are almost undetectable by 2 
DPE (Fig. 2.1B). Thus, a significant fraction of animals are able to survive for many days 
with very low levels of dSMN. 
To determine whether a correlation exists between dSMN and snRNA levels, 
developmentally staged Smn-/- and OR larvae were harvested and then split into two 
groups of ~20-50 animals each. One group was used to extract protein for western 
analysis and the other was placed in TRIZOL for RNA extraction and northern blotting 
(Fig. 2.1C). The snRNA levels in both OR and Smn null flies were greatest on day 1 post 
egg laying, after which time they decreased and remained at a constant level throughout 
larval development. This was a surprising finding in the mutant larvae, since dSMN 
levels are severely reduced by day 2 and yet, no dramatic or progressive reduction in 
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snRNA levels was observed. We did note a slight decrease in U1, U5 and U11 snRNA 
levels in the mutants and a greater decrease in the levels of U12 and U4atac snRNAs 
(Fig. 2.1C). These findings are consistent with observations in the mammalian system 
that minor class snRNAs (particularly U4atac and U12) are more sensitive to SMN 
depletion (Gabanella et al., 2007; Workman et al., 2009). We also note that levels of 
U6atac appear to be upregulated in the Smn-/- larvae, although the molecular basis for this 
is currently unknown. We did not detect an increase in levels of unassembled snRNAs in 
mutant larvae, as shown by co-immunoprecipitation with anti-Sm antibody, Y12 (Fig. 
S2.1). Thus, as observed in mammalian cell culture systems (Sauterer et al., 1988) total 
Drosophila snRNA levels reflect total snRNP levels. 
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Figure 2.1. Characterization of Smn null flies. A. Smn-/- mutants begin dying 4 days post 
egg laying (DPE), with a number of larvae surviving for extended periods without 
pupariation. Note that by 6 DPE the OR control larvae had all pupated. For each 
genotype n ≥ 100 larvae, collected on day 1 post egg laying. B. Developmental western 
blot of dSMN levels in control (OR) and Smn null animals. C. Developmental northern 
blot showing major and minor class spliceosomal snRNA levels in OR and Smn null 
larvae. Note that there is no progressive decrease in snRNA levels as the larvae age. 7SK 
and U6 snRNA are shown as loading controls. These snRNA levels are reflective of the 
total snRNP levels as shown in Fig. S2.1. An asterisk marks a heteroallelic variant U11 











In addition to the canonical forms, we observed expression of U5 and U11 
snRNA variants. Consistent with a previous report, the variant forms of U5 are 
predominantly expressed early in larval development (Chen et al., 2005). The Smn-/- 
larvae express a variant form of U11, that contains a 22 bp deletion in stem loop II, a 
region that is not well conserved among Drosophilid species (Fig. S2.2A). The U11 and 
Smn genes are both on the same chromosome, and we note that this U11 variant tracks 
with the SmnD allele and is not present on the homolog containing SmnX7 (Fig. S2.2B). 
We also note that the variant U11 snRNA can be immunoprecipitated by anti-Sm 
antibodies (Fig. S2.2C) and that SmnD homozygotes can be rescued by transgenic 
expression of dSMN (Rajendra et al., 2007, this work). Thus, this variant U11 allele 
appears to be fully functional. 
Characterization of the Smn-/- flies reveals that dSMN levels are severely reduced 
early in larval development, yet a significant fraction of larvae are able to survive for 
many days without dSMN. We observed a decrease in the levels of U4atac and U12 
snRNAs in Smn null larvae. However, this decrease was neither exacerbated by 
prolonged reduction of dSMN, nor did it result in appreciable defects in the splicing of 
minor-class (U12-type) introns. Real-time quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) analysis was used to measure levels of spliced U12-dependent 
intron containing mRNAs (Fig. S2.4) in Smn-/- larvae relative to wild-type larvae (Fig. 
2.2). U6atac-/- larvae, which are known to be defective in U12-dependent splicing (Otake 
et al., 2002; Pessa et al., 2010), were used as positive controls. As shown in Figure 2-2, 
mRNAs from these genes were significantly reduced in U6atac mutants, whereas those 
same mRNAs were largely unaffected in Smn mutants. 
  
Figure 2.2. Analysis of minor
qRT-PCR was used to measure the relative levels of spliced mRNA for eighteen genes 
containing putative U12-dependent introns in ~76 hour OR, 
using Rpl32 for normalization. Primers for qRT
exon-exon junction flanking the U12
be detected (inset). Levels of spliced mRNA in the mutants have been normalized to 
those of OR larvae.  The U6atac
introns for all the mRNAs tested (group avg. = 0.32). Nine of the eighteen mRNAs were 
reduced in U6atac-/- animals with p
one mRNA approached, but did not reach, significance (CG7892, p ~ 0.08). In contrast, 
splicing of these same introns was relatively unaffected in
1.06). Although a majority of the mRNAs were not affected, we note that the four 
mRNAs showing the greatest decrease in the 
affected mRNAs in U6atac-/-
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-values < 0.01, eight had p < 0.05 and the levels of 
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Transgenic expression of an SMA patient-derived mutation in dSMN rescues Smn-/- larval 
lethality 
Although analysis of Smn null mutants is informative, the many putative functions 
of SMN make it difficult to parse out the precise cause of lethality in these animals. Thus 
we wanted to develop Drosophila SMA models that perturb a subset of SMN functions, 
providing increased resolution to the analysis. As a proof of principle, we created flies 
expressing an SMA patient-derived point mutation, T205I. This mutation corresponds to 
an SMA type II/III patient mutation, T274I, which is located in the YG box domain of 
SMN (Hahnen et al., 1997; Sun et al., 2005). We used the PhiC31 integrase system 
(Bischof et al., 2007) to generate transgenic flies carrying either a wild-type (WT) or a 
T205I mutant transgene, inserted at site 86Fb on chromosome 3. To preserve endogenous 
expression patterns, the constructs are driven by the native Smn promoter, and contain 
native 3' and 5' flanking sequences. The transgenic proteins can be distinguished from the 
endogenous ones by the presence of an N-terminal 3X FLAG tag. 
Expression of the wild-type construct (SmnWT) in the Smn-/- background results in 
>70% rescue of lethality (Fig. 2.3A). The surviving adults are fertile, with no apparent 
defects in flight or motility. In contrast with the null phenotype, expression of the 
SmnT205I, construct rescues larval lethality; ~25% of these animals eclose as adults, but 
the majority of them die as pupae (Fig. 2.3A). This partial rescue of Smn-/- animals is 
consistent with the human T274I mutation, which causes a relatively mild form of SMA 
(Sun et al., 2005). Note that both the WT and T205I rescue animals show some 
developmental delay as they pupate and eclose a day later than OR controls. 
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dSMNT205I is moderately defective in self-oligmerization  
A number of human SMA-derived mutations in the YG box region of SMN, 
including SMNT274I, have been shown to be defective in oligomerization (Lorson et al., 
1998). We tested a panel of dSMN proteins, including T205I, for similar defects. FLAG- 
and Myc-tagged versions of each construct were expressed in Drosophila S2 cells and the 
co-immunoprecipitation profiles were compared (Fig. 2.3B). Immunoprecipitation was 
performed with anti-FLAG antibody and the amount of Myc-tagged protein that co-
precipitated was measured. The amount of Myc-dSMN(T205I) precipitated by FLAG-
dSMN(T205I) was reduced compared to the amount of Myc-dSMN(WT) precipitated by 
FLAG-dSMN(WT), indicating a deficiency in its ability to self-oligomerize. This 
conservation between the human and fly SMN mutants also extends to the following 
SMA-derived point mutations. Both SmnG206S (corresponding to human SMNG275S) and 
SmnY203C (SMNY272C) mutants were defective in oligomerization, similar to reports of their 
mammalian counterparts (Lorson et al., 1998). Furthermore, the severity of these defects 
is also conserved, as Y203C was less effective at binding to itself than either T205I or 
G206S (Fig. 2.3D). Likewise, the oligomerization defect of Y272C is known to be more 
severe than that of T274I (Lorson et al., 1998). Thus, T205I displays a relatively mild 
defect in self-oligomerization. 
In many multi-protein complexes, factors that fail to enter the complex are 
degraded. Such is the case with SMN (Burnett et al., 2009). Thus we expected that T205I 
transgenic flies might display reduced levels of FLAG-dSMN compared to transgenic 
flies expressing WT FLAG-dSMN. However, levels of FLAG-dSMN in both the WT and 
T205I transgenic lines were equivalent, as analyzed by western blotting (Fig.  2.3C). This 
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finding indicates that the relatively mild defect in T205I oligomerization does not 
significantly affect dSMN levels. In addition, this suggests that the lethality of the T205I 
point mutant is not due to insufficient protein levels, but rather due to a molecular defect 
in dSMN. 
As shown in Figure 2-3C, expression of both transgenic FLAG-dSMN constructs 
(WT and T205I) was significantly below the level of endogenous dSMN. The 
considerable degree of rescue achieved with such low expression levels shows that 
dSMN is made in greater quantities than required by the fly. Similar observations have 
been made in mammalian cell lines wherein the phenotypic effects of SMN reduction are 
observed only when SMN levels are reduced by 85-95% (Zhang et al., 2008; Bowerman 
et al., 2011). Interestingly, we found that expression of the WT transgene with an 
Actin5C promoter failed to rescue the null mutant beyond pupal stages, despite the fact 
that this construct expressed much higher levels of dSMN protein than the native 
promoter driven construct (Fig. 2.3D). These results suggest that the Actin5C promoter 
fails to express dSMN in some critical tissue or developmental window. 
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Figure 2.3. Transgenic rescue of Smn null animals with an SMA patient-derived point 
mutation, T205I. A. Transgenic rescue analysis of Smn null flies with SmnWT and SmnT205I 
constructs. Approximately 100 first instar larvae were collected and the fraction of live 
animals at subsequent developmental stages was measured. B. dSMN(T205I) shows mild 
oligomerization defects. Lysates were prepared from cells co-expressing FLAG and Myc 
tagged versions of each dSMN point mutant and WT. Co-immunoprecipitation with anti-
FLAG antibody followed by western with anti-Myc antibody showed that mutants 
G206S, T205I and Y203C were defective in oligomerization. C. Western blot of lysates 
from SmnWT and SmnT205I larvae and pupae, probed with anti-SMN antibody. The 
transgenic proteins migrate slower than endogenous dSMN due to the presence of the 3X 
FLAG tag. Tubulin was used as a loading control. D. Western analysis of lysates from 
flies heterozygous for the native and Actin5C promoter-driven FLAG-Smn constructs. 
Blots were probed with anti-SMN; anti-tubulin was used as a loading control. E. SmnWT 
and SmnT205I animals rescued locomotion defects present in Smn-/- larvae. Graph shows 
the performance of Smn-/-, SmnWT and SmnT205I larvae compared to OR in the righting 
assay. At least 18 larvae were measured for each genotype and Student’s T-test was used 
to calculate p-values. *, p < 0.05; **, p < 0.01; ***, p < 0.0001. F. Graph illustrating 
results of the burrowing assay for OR, Smn-/-, SmnWT and SmnT205I larvae. A chi-squared 





Transgenic expression of SmnT205I rescues larval locomotion 
Consistent with previous reports (Chan et al., 2003; Rajendra et al., 2007; 
Shpargel et al., 2009), we found that Smn-/- animals display significant defects in larval 
locomotion. To further characterize these locomotor defects, we employed two 
previously described assays (Wu et al., 2003; Ubhi et al., 2007). In the ‘righting’ assay, 
each larva was placed on its dorsal surface and the time taken to return to its ventral 
surface (the crawling position) was measured (Fig. 2.3E). The Smn-/- larvae took a 
significantly longer time to return to the crawling position compared to OR. Larval 
motility was rescued in animals carrying the WT transgene, and to a large extent in the 
T205I transgenic animals, which showed a relatively mild defect. In the ‘burrowing’ 
assay, ~30 larvae were placed atop a dish containing 1.5% agar/molasses media and 
incubated at room temperature in the dark. After 2 hours, the number of larvae remaining 
on top of the medium was recorded. The assay was repeated 3 times per genotype. We 
found that the Smn-/- mutants do not burrow into the medium at all (Fig. 2.3F). However, 
we also noticed that if there were surface defects (cuts) present in the media, some of 
these larvae worked themselves into the crevices. Importantly, the burrowing behavior 
was restored in both the WT and T205I transgenic animals (Fig. 2.3F). We conclude that 
SmnT205I rescues the larval viability and locomotor defects observed in the null mutants. 
SmnT205I and SmnWT transgenic larvae are functional in snRNP biogenesis 
Phenotypically, the SmnT205I flies more closely resemble SmnWT animals than they 
do the Smn null mutants. To determine the degree to which this resemblance extends to 
the molecular level, we quantified the snRNAs in Smn-/-, SmnWT and SmnT205I animals. 
Larvae from each of the three aforementioned genotypes, along with OR, were harvested 
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just prior to the beginning of the lethal phase (i.e. at ~76 hours) and snRNA levels were 
analyzed by northern blotting (Fig. 2.4A). As noted earlier, U1, U4, U5, U11, U12 and 
U4atac snRNAs showed a reduction in the null animals (Fig. 2.4B). Again, U12 and 
U4atac levels were the most severely affected (~60% reduction). The SmnWT and SmnT205I 
animals showed very similar snRNA profiles, despite differences in adult viability. Both 
transgenes failed to rescue U1, U4 and U4atac snRNA levels and only partially rescued 
U12 and U5 snRNAs (Fig. 2.4B). Thus, we conclude that the SmnT205I mutant is 
functional in snRNP biogenesis. In support of this interpretation, the human counterpart 
to this mutation, SMNT274I, was shown to be active in a HeLa cell Sm-core snRNP 
assembly assay (Shpargel et al., 2005). 
We also analyzed minor-class intron splicing in the two transgenic rescue lines. 
Among the four mRNAs that showed slight but significant reductions in the Smn null 
mutant background (Fig. 2.2), there was no correlation among the SmnWT and SmnT205I 
samples (Fig. S2.3). Two of the mRNAs (CG18177 and CG15081) showed no significant 
differences upon expression of either transgene. CG11839 mRNA was restored to OR 
levels only by expression of SmnWT, whereas CG33108 levels were restored only by 
expression of SmnT205I (Fig. S2.3).  
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Figure 2.4. SmnWT and SmnT205I animals have similar snRNA profiles. A. Representative 
northern blot, showing levels of major and minor class snRNAs in ~76 hour larvae from 
OR, Smn-/-, SmnWT and SmnT205I lines. U6 snRNA is shown as the loading control. B. 
Graph illustrating the relative levels of snRNAs in Smn-/-, SmnWT and SmnT205I larvae 
compared to OR. Northern blots from at least four biological replicates were used to 
quantify snRNA levels, using U6 for normalization. All the Sm-class snRNAs, except for 
U2, were reduced in Smn-/- mutants, with U4, U5, U11, U12 and U4atac (p ~ 0.001) 
showing the greatest reduction. SmnWT and SmnT205I transgenic animals showed increased 
levels of U12 compared to Smn-/- animals (p < 0.001) but did not show a significant 
difference in the levels of U1, U4, U11 and U4atac (p > 0.05). SmnWT and SmnT205I 
animals also displayed a slight increase in U5 snRNA levels compared to the Smn-/- 
larvae (p ~0.001 and ~0.045, respectively), although both remained well below those of 






































SmnT205I is a good model for intermediate SMA  
An analysis of SMN point mutations that potentially disrupt only a subset of 
interactions should be informative in elucidating the contributions of individual SMN 
functions to the overall phenotype. The human SMNT274I mutation was identified in 
patients with milder forms of SMA, types II/III (Hahnen et al., 1997; Sun et al., 2005). 
These patients show a later age of onset, decreased severity of symptoms and longer life 
expectancy than type I patients (Ogino et al., 2004). The Drosophila equivalent of this 
mutation, SmnT205I, recapitulates several key features of intermediate SMA, including a 
slight deficiency in motor function and a much longer lifespan than the null mutant. We 
also observed a mild defect in oligomerization of SmnT205I, suggesting that on a molecular 
level, this Drosophila protein behaves similarly to the human mutation. We conclude that 
the SmnT205I flies represent a good model for intermediate SMA. 
SMN, snRNA levels and SMA 
As shown above, transgenic expression of SmnWT was able to rescue the 
locomotion and viability defects observed in Smn null mutants, however, a majority of 
the snRNAs were largely unrestored to wild-type levels. Given the considerable degree of 
phenotypic rescue, this was an unexpected finding, suggesting that the observed 
reduction in snRNAs in the null animals is not a major contributor to larval locomotion 
and viability.  
Consistent with our findings, previous studies using mouse models of SMA have 
also reported decreases in snRNA levels, particularly for U12 and U4atac (Gabanella et 
al., 2007, Workman et al., 2009). Other investigators reported widespread pre-mRNA 
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splicing changes in both minor- and major-class introns in late-symptomatic SMA mice 
(Zhang et al., 2008). However, subsequent studies revealed that these splicing defects are 
likely a secondary consequence of severe SMN loss, as pre- and early-symptomatic SMA 
mice did not show an enrichment of unspliced introns (Baumer et al., 2009). 
In our Drosophila system, we note that U12 and (to a lesser extent) U5 levels 
were partially rescued by transgenic expression of SmnWT and SmnT205I, although U4atac 
levels remained low (Fig. 2.4B). Thus, one explanation for our results could be that 
splicing of minor-class (U12-specific) introns is sensitive to small changes in snRNA 
concentrations and that U12 and U5 are limiting factors, whereas U4atac is not. We 
tested this hypothesis by using qRT-PCR to measure mRNA levels in 18 of the 20 
predicted minor-class (U12-specific) introns in the Drosophila transcriptome (Lin et al., 
2010). As shown in Figure 2-2, a mutation in the U6atac gene resulted in pronounced 
defects in splicing of minor-class introns, however, splicing of these same mRNAs was 
largely unaffected in Smn null mutants. Among the minor-intron transcripts we analyzed, 
the steady-state levels of two mRNAs, CG15081 (Phb2 in mice) and CG33108 (ortholog 
unknown), were reduced by roughly 50% in Smn-/- larvae. It is possible that reduction in 
levels of one or more of these mRNAs could contribute to the phenotype of Smn null 
mutants, however, CG15081 heterozygotes are completely viable (Flybase). A similar 
decrease in levels of the Phb2 mRNA in mice was shown to affect neither organismal 
viability nor motor function (Park et al., 2011), strongly suggesting that 
haploinsufficiency for CG15081 is not the cause of the Smn phenotype.  
These observations question the significance of snRNA levels in human SMA 
etiology. In this regard, it is important to note that recessive point mutations in the gene 
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encoding human U4atac snRNA do not phenocopy SMA. Instead, loss of U4atac function 
causes a disease known as microcephalic osteodysplastic primordial dwarfism type I 
(MOPD I), which is characterized by severe intrauterine growth retardation and multiple 
organ abnormalities (Edery et al., 2011; He et al., 2011). Similar to the fruitfly U6atac 
mutants (Pessa et al., 2010; this work), cells derived from MOPD I patients display 
marked defects in splicing of minor-class (U12-type) introns, whereas splicing of major-
class (U2-type) introns is unaffected (Edery et al., 2011; He et al., 2011). Although we 
cannot entirely exclude the possibility that tissue-specific defects in minor-intron splicing 
may be causative for SMA, our finding that transgenic expression of SmnWT can rescue 
viability and fertility without restoring U4atac levels effectively uncouples the observed 
global snRNA deficits from the organismal phenotype. Moreover, it is important to note 
that the Smn and U6atac mutants were analyzed just prior to onset of the lethal phase. At 
this developmental timepoint, Smn null animals already display significant motor 
function defects. We therefore conclude that perturbations in minor spliceosome levels 
are not likely to be causative for the larval locomotion and viability defects observed in 
Smn null mutants. 
With the possible exception of U5, SmnT205I animals have nearly identical snRNA 
profiles to those of the SmnWT animals, yet most of the T205I animals die as pupae. Given 
the intermediate phenotype of both humans and fruit flies expressing the T274I/T205I 
mutation and the fact that human SMNT274I is active in Sm-core assembly (Shpargel and 
Matera, 2005), these findings strongly suggest that mutation of this residue disrupts a 
second, essential function of SMN protein. This does not mean that splicing plays no role 
in downstream SMA pathology; it clearly does. There is strong evidence for a negative 
 45
feedback loop wherein low levels of SMN protein exacerbate exon skipping of human 
SMN2, leading to a further reduction in SMN expression (Jodelka et al., 2010; Ruggiu et 
al., 2011). However, because Smn is a single-exon gene in Drosophila, our system also 
uncouples protein-based defects in SMN from autologous feedback regulation via 
splicing. In conclusion, our results demonstrate that the reduction in snRNA levels 
observed in Smn mutants is not a major contributor to organismal lethality, and indicate 
that non-snRNP biogenesis functions of SMN play critical roles in the etiology of SMA. 
Molecular identification of this second SMN function will be an important subject of 
future investigation. 
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Table S2.1. Descriptions of 18 minor-class intron containing genes in the Drosophila 
genome that were tested via qRT-PCR in figure 2-2. Adapted from Lin et al, 2010. 
 
 
 CHAPTER III 
The development and characterization of new Drosophila models of  
Spinal Muscular Atrophy 
Introduction 
The common childhood disorder, spinal muscular atrophy (SMA), is caused by 
mutations in survival motor neuron 1 (SMN1). Approximately 95% of SMA patients have 
deletions in SMN1, whereas the remaining 5% have point mutations in SMN1 (Burghes 
and Beattie, 2009). Despite much progress in elucidating the functions of SMN, the 
etiology of SMA remains poorly understood. To date, SMN’s most well understood 
function is in the biogenesis of spliceosomal uridine-rich small nuclear 
ribonucleoproteins (snRNPs). Several putative neuron and muscle-specific functions for 
SMN have also been described (Fan et al., 2002; McWhorter et al., 2003; Sharma et al., 
2005). However, no convincing link between any function of SMN and SMA etiology 
has been shown. Thus the key question in SMA research is to understand which function 
or functions of SMN are critical in causing the disease.  
 In Chapter II, we showed evidence suggesting that non-snRNP related functions 
of SMN are important in SMA etiology using an SMA patient-derived point mutation, 
SmnT205I, in Drosophila Smn. Here, we extend the analysis to an entire series of 
transgenic flies expressing patient-derived point mutations. We show that these missense 
mutations recapitulate the range of phenotypic severities observed in human SMA, 
validating the use of the Drosophila system to understand their mechanism of action. 
 51
Further, we show that several of these mutations, three previously characterized in 
humans and one uncharacterized, disrupt interactions with known SMN binding partners 
in a manner similar to their human counterparts. Therefore these new Drosophila models 
of SMA should provide mechanistic insight that is directly applicable to the etiology of 
SMA in humans.  
Experimental Procedures 
Fly stocks 
Oregon-R was used as the wild-type allele. The SmnX7 microdeletion allele 
(Chang et al., 2008) was a gift from S. Artavanis-Tsakonis (Harvard University, 
Cambridge, USA). The fly line carrying the 86Fb landing site was obtained from the 
Bloomington Stock Center (IN, USA). All stocks were cultured on molasses and agar at 
room temperature (24 ± 1°C). The transgenes were injected into embryos by BestGene 
Inc. (Chino Hills, CA).  
Rescue constructs 
A ~3kb fragment containing the entire Smn coding region was cloned from the 
Drosophila genome into the pAttB vector (Bischof et al. 2007). A 3X FLAG tag was 
inserted downstream of the start codon of dSMN. The point mutations were introduced 
into this construct using Quickchange (Invitrogen) site-directed mutagenesis according to 
manufacturer’s instructions. 
Antibodies and Western blotting 
Larval lysates were prepared by crushing the animals in lysis buffer (50mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1mM EDTA, 1% NP-40) with 1X protease inhibitor cocktail 
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(Invitrogen) and clearing the lysate by centrifugation at 13,000 RPM for 10 min at 4ºC. 
Western blotting on lysates was performed using standard protocols. Rabbit anti-dSMN 
serum was generated by injecting rabbits with purified, full-length dSMN protein (Pacific 
Immunology Corp, CA), and was subsequently affinity purified. For Western blotting, 
dilutions of 1 in 2,500 for the affinity purified anti-dSMN, 1 in 10,000 for anti-α tubulin 
(Sigma), 1 in 10,000 for monoclonal anti-FLAG (Sigma), 1 in 10,000 for polyclonal anti-
Myc and 1 in 5000 for monoclonal anti-Myc (Santa Cruz) were used. Anti-FLAG 
antibody crosslinked to agarose beads (EZview Red Anti-FLAG M2 affinity gel, Sigma) 
or anti-Myc antibody crosslinked to agarose beads (Sigma) were used to 
immunoprecipitate FLAG and Myc tagged proteins from cells. 
 
Results 
Creating SMA patient-derived point mutations in Drosophila SMN 
In order to identify which functions of SMN are critical to the pathology of SMA, 
we wanted to create disease-relevant models that disrupt only subsets of SMN functions. 
Point mutations are useful in this context as they can disrupt specific functions of multi-
domain proteins such as SMN, while leaving others functions unaffected. Twenty-five 
different SMN1 point mutations have been identified to date in SMA patients (Burghes 
and Beattie, 2009). Of these, twelve mutations are at residues that are conserved between 
humans and Drosophila (Fig. 3.1). Using site-directed mutagenesis we created the same 
twelve mutations in Drosophila Smn. An additional mutation was created, derived from 
hSMN(E134K) mutation. This residue is not conserved in Drosophila so we changed a 
neighbouring conserved glutamate to lysine in an attempt to mimic the human mutation. 
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Of the thirteen mutations created, one lies in the Gemin2 binding site of SMN, six are in 
the Tudor domain and six in the YG box oligomerization domain, thus representing the 






Figure 3.1. An alignment of SMN protein from human and various species including 
Drosophila. In red are residues that are sites of point mutations in SMA patients, and are 
























Figure 3.2. SMA patient mutations in 
spread of SMA patient derived point mutations in 
point mutations created in Drosophila
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Mutation Location Reference 
D44V N-terminal Sun et al, 2005 
W92S Tudor domain Kotani et al., 2007 
V94G Tudor domain Clermont et al., 2004 
G95R Tudor domain Sun et al., 2005 
I116F Tudor domain Cusco et al., 2004 
Y130C Tudor domain Prior, 2007 
M263R YG box Clermont et al, 2004 
Y272C YG box Wirth et al., 1999 
T274I YG box Wirth et al, 1999 
G275S YG box Wirth, 2000 
G279V YG box Wirth et al, 2000 





Characterizing interactions of SMA point mutations in dSMN 
 To understand how these mutations might affect the function of SMN, we tested 
their interactions with known binding partners of SMN. The mutant proteins were N-
terminally tagged with a 3X FLAG tag to distinguish them from the endogenous dSMN, 
and co-transfected into S2 cells (a Drosophila embryonic cell line) with a Myc-tagged 
SMN binding partner. Immunoprecipitation was performed for either the FLAG- or Myc- 
tagged proteins and the amount of co-precipitating protein was visualized via western 
blotting. The point mutant SmnD20V showed significantly reduced interaction with 
Gemin2 (Fig. 3.3A). This was not a surprising finding as this mutation lies in the Gemin2 
binding domain of SMN, and is consistent with what has been observed for its human 
counterpart, SMND44V (Ogawa et al., 2007; Zhang et al., 2011). Gemin3 binding was 
severely disrupted by two point mutations, SmnY203C (SMNY272C in humans) and SmnG206S 
(SMNG275S) (Fig. 3.3B). Notably, the SmnT205I (SMNT274I) mutation, which lies directly 
between the Y203C and G206S mutations, did not affect interaction with Gemin3 (Fig. 
3.3C). 
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Figure 3.3. Interaction of SMA patient derived mutations in dSMN with dGemin2 and 
dGemin3. A. Lysates from S2 cells co-expressing FLAG tagged dSMN mutants and Myc 
tagged dGemin2 were immunoprecipitated with anti-FLAG antibody. Western blot shows 
the amount of Myc tagged dGemin2 co-precipitating with the indicated mutant proteins. 
The D20V mutation in dSMN reduces its interaction with dGemin2. B. Lysates from S2 
cells co-expressing FLAG tagged dSMN mutants and Myc tagged dGemin3 were 
immunoprecipitated with anti-Myc antibody. Co-precipitating FLAG-dSMN mutants 
were visualized by Western. The mutations Y203C and G206S cause severe defects in 
binding of dSMN to dGemin3. C. In a similar experiment to B, dSMN mutation T205I, a 
residue that lies in between Y203C and G206S, did not show any defects in binding 
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As described in Chapter II, SmnT205I, SmnG206S and SmnY203C displayed defects in 
oligomerization ranging from mild to severe, in agreement with observations in the 
human system (Fig. 2.2). Preliminary analysis shows that although these mutants show 
defects in self-oligomerization, they are capable of interacting with WT dSMN (Fig. 
S3.1). We also analyzed interactions of dSMN with a number of other known binding 
partners (Table S3-I). We failed to detect robust interaction of dSMN with the majority of 
them including Profilin, Unrip, Fimbrin (Plastin3), and, surprisingly, SmB. It is possible 
that our assay conditions were not optimal to detect all these interactions, which may be 
weak or transient compared to interactions with the Gemins.  
Drosophila SMN point mutants recapitulate the range of phenotypic severity seen in SMA 
patients 
To characterize the effect of SMA patient mutations in vivo, we generated 
transgenic flies using the PhiC31 method of site-directed insertion into the genome 
(Bischof et al, 2007). The SmnX7 mutation was recombined with the 86Fb landing site, the 
PhiC31 integrase on the X chromosome was brought into this background, and resulting 
flies were used for transgenesis. Thus, the point mutant transgenes were injected directly 
into the SmnX7/TM6.tb background (Fig. S3.2). To maintain native patterns of expression, 
the transgenes are expressed from the native promoter and contain native 5` and 3` UTRs 
and transcription termination sequences (Fig. 3.4A).  The experimental design is the same 
as that used to express the SmnWT and SmnT205I transgenes described in Chapter II. 
Western analysis was used to confirm the expression of transgenic proteins (Fig. 
3.4B,C,D). As all the transgenes were inserted at the same location, any differences in 
expression are most likely due to differences in protein stability rather than RNA 
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transcription. The expression level of FLAG-dSMN was similar to the WT transgenic 
line for the majority of transgenic flies, indicating that the mutant proteins had similar 
stabilities to the WT protein (Fig. 3.4). Three mutants, SmnM194R, SmnG206S and SmnY203C 
showed significantly reduced levels of dSMN, suggesting that these proteins may be 
unstable (Fig. 3.4D).  
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Figure 3.4. Expression of SMA patient derived missense mutations in flies. A. Design of 
the construct used to create SMA point mutations in the fly. dSMN was expressed using 
native promoter and termination sequences contained within the ~1.4 Kbp 5` and 0.4 Kbp 
3` regions, respectively. B and C. Western blot of larval lysates from the different 
homozygous mutant lines indicated, probed with anti-dSMN antibody. The slower 
migrating band represents FLAG-dSMN and the faster is the endogenous protein. D. 
Same genotypes as shown in C were probed with the more sensitive anti-FLAG antibody 
to better visualize protein levels in SmnM194R, SmnY203C and SmnG206S. Tubulin is used as a 





























As observed in Chapter II, the transgenic flies also expressed lower levels of 
dSMN compared to the amount of endogenous protein. The same constructs inserted at 
another genomic site, 68A4 (attP2), showed decreased expression compared to the 86Fb 
insertion, and failed to rescue viability (Fig. S3.3). This suggests that the level of 
expression from the 86Fb site is likely to be limiting and just sufficient to rescue viability 
of Smn null mutants.  
For phenotypic analysis of the point mutants, we crossed the transgenic flies to 
the SmnX7 allele. This approach was adopted because we observed an improvement in the 
viability of the transgenic mutants when crossed to SmnX7 compared to the self-cross. 
This indicated the presence of recessive alleles in the background that were contributing 
to the phenotype. Fig. 3.5 shows the results of the phenotypic analysis of the mutants. 
Three mutations (SmnG206S, SmnY203C and SmnM194R) did not show any rescue of the 
phenotype; all animals died as larvae (Fig. 3.5A). Notably, SmnG206S did give rise to a 
very small percentage (~3%) of pseudopupae, which we have not observed in SmnX7 
animals. Interestingly, the number of larvae reaching pupal stages varied between the 
mutants, and this number did not correlate with the number of flies that eclosed (Fig. 
3.5B). Surprisingly, quite a few mutations showed near complete rescue of the Smn null 
phenotype. These include SmnD20V, SmnG73R, SmnI93F, SmnF70S and SmnE112K. It should be 
noted that SmnE112K is not a true mimic of the human mutation SMNE134K since this 
residue is not conserved in flies. Therefore, the phenotype of this mutant may not be 
relevant to the human disease. The majority of SmnG210C and SmnT205I flies did not eclose. 
The SmnY107C and SmnG210V mutants were essentially pupal lethal with a very low 
eclosion rate of ~18% and ~5%, respectively. Interestingly, SmnV72G was the only 
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mutation to show early pupal lethality, where pupae appeared to die before reaching the 
pharate adult stages. The point mutant alleles of Smn thus recapitulate the range of 
phenotypic severity that is observed in SMA patients (Fig. 3.2B). 
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Figure 3.5. Viability analyses of SMA patient derived point mutations in flies. A. Graph 
showing the level of rescue (number of flies/number of larvae collected) obtained for the 
specified mutant line when crossed with SmnX7. For each genotype ~70-100 larvae were 
collected at first instar and then followed through development. B. The numbers of live 
larvae over time are shown for the three mutant lines, SmnM194R, SmnY203C and SmnG206S 
that did not rescue the larval lethality of SmnX7. Note that between 5-6 DPE, Oregon-R 
controls have pupated. C. Graph showing the level of rescue of each mutant when co-
expressed with the WT transgene (dark blue bars) and when expressed alone i.e. crossed 
with SmnX7 (light blue bars). Note that for the WT genotype, the dark blue bar represents 
a cross between two transgenic founder lines (two copies of WT transgene). D. A 
summary of the phenotype of SMA point mutations in Drosophila and their 
corresponding phenotypes in humans. The number of SMN2 genes is also given. The 

































 Human mutation SMA type SMN2 copies
 D44V III 
 W92S I 
 G95R III 
 I116F I 
  
 G279C II/III Not known
 T274I II/III 
  
 Y130C III 
 G279V I Not known
  
 V94G II 
  
 M263R I 
 Y272C I/II/IIIb 




















To further characterize the mutant lines, we crossed each mutant with the wild-
type (WT) transgenic line, Smn-/-, SmnWT. Since these mutations show a recessive mode 
of inheritance in patients, we expected rescue of viability to the same extent as for Smn-/-, 
SmnWT self-cross, or at the least, Smn-/-, SmnWT crossed with SmnX7 (~66%). However, for 
many mutations we observed an intermediate level of rescue (Fig. 3.5D), between the 
level observed when expressing WT transgene alone and the mutant transgenes alone 
(Fig. 3.4B). This was most evident for SmnM194R, SmnY203C and SmnG206S, which did not 
rescue larval lethality when crossed with SmnX7 but showed approximately 8-16% 
eclosion when expressed along with the WT transgene.  
The intercross of two WT transgenic lines from different founders showed a lower 
viability than a cross of the WT transgene with SmnX7. This was surprising, as the former 
cross has two copies of the transgene, while the latter has just one. However, it is possible 
that the ‘outcross’ to SmnX7 reduces the effects of deleterious second-site recessive 
alleles, thus making the progeny of this cross healthier than those of the intercross of WT 
clones. This variable could also be affecting the results obtained for the crosses of mutant 
transgene with WT transgene since they are all inserted into the same genetic 
background.  
Notably, the level of rescue observed for the mutants when expressed with SmnWT 
correlated with their phenotypic severity when expressed alone. For example, SmnG210V 
had a less severe phenotype (pupal lethal) than SmnG206S (larval lethal) when expressed 
alone, and when expressed with the WT protein, SmnG210V also showed greater viability 
than SmnG206S (Fig. 3.5D). There was one exception to this; SmnV72G had an early pupal 
lethal phenotype when expressed alone, but showed an eclosion rate comparable to the 
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milder mutations when co-expressed with the WT protein. Overall, these findings suggest 
that the intermediate phenotype observed in these crosses is a result of incomplete 
dominance.  
Discussion 
In this work, we have described new Drosophila SMA models created by the 
expression of SMA patient-derived point mutations in Drosophila SMN. All available 
SMN mutations in the fly are effectively null, including two point mutations created by 
EMS mutagenesis (Chan et al, 2003). While these models are extremely useful, they have 
two key disadvantages in the study of SMA: they do not recapitulate the human disorder, 
which is born from a reduction of SMN; they disrupt all potential functions of SMN and 
thus do not help pin-point which functions may play critical roles in SMA pathology. The 
fly lines we have generated should be useful in these contexts, as they recapitulate 
mutations identified in SMA patients. Thus their analysis will be directly relevant to the 
human disease. Further, being point mutations, they may affect only a subset of SMN 
functions rather than all of them.  
SMA mutations in humans and flies 
The similarities in molecular interactions between SMA mutations in human and 
fly SMN suggest that their mechanisms of pathology are conserved. Thus, information 
that we learn from the fly system should be directly applicable to human SMA biology. 
As an example, the SMNY272C mutation (SmnY203C in flies) was previously shown to have 
reduced binding to Gemin3 (Charroux et al. 1999), however, the SMNG275S (SmnG206S) 
mutation has not been characterized in this context before. From our finding that 
SmnG206S also disrupts binding with dGemin3, we can hypothesize that this residue is 
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important for Gemin3 binding in human SMN as well. Similarly, the oligomerization 
defect observed for dSMN(G206S) suggests that hSMN(G275S) would also be impaired 
in oligomerization. We do note that hSMN(G279V) is documented to have 
oligomerization defects, however, the Drosophila counterpart, dSMN(G210V), does not 
show a defect in our assay. 
We have shown previously that SMN levels are severely reduced in the absence 
of Gemin3 in Drosophila, suggesting that dGemin3 is important for dSMN stability 
(Shpargel et al., 2009). Consistent with this observation, both mutants that are deficient in 
binding to dGemin3, dSMN(Y203C) and dSMN(G206S), are relatively unstable in vivo. 
SMN protein that cannot enter into complexes is preferentially degraded (Burnett et al., 
2009). However, the instability of these mutant proteins may not be entirely explained by 
a failure to oligomerize.  For example, dSMN(G206S) shows a similar defect in self-
binding as dSMN(T205I), however, dSMN(T205I) is relatively stable in vivo. 
dSMN(T205I) also does not display defects in dGemin3 binding, thus uncoupling this 
interaction from the oligomerization defect (Fig. 3.3C). Collectively, these observations 
suggest that the inability to bind dGemin3 is a major factor in the instability of the 
Y203C and G206S mutants. It would be interesting to test whether dSMN(M194R), 
which is also unstable in vivo, is defective in binding dGemin3. No effect on SMN levels 
after transient Gemin3 knockdown via RNAi in mammalian cells has been reported. 
However, the knockdown of Gemin3 did not completely deplete the protein in these cells 
(Shpargel et al, 2005; Feng et al, 2005). Thus, to definitively determine whether this 
relationship between SMN and Gemin3 is unique to Drosophila or conserved in 
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mammals, SMN levels should be tested in Gemin3 null mutant mouse embryos (Mouillet 
et al., 2008). 
Drosophila models of SMA point mutations 
The viability phenotypes of several of the missense mutations in flies are 
concordant with those documented for their human counterparts (Fig. 3.5D). Two of the 
mutants that produce severe phenotypes (larval lethality), SmnY203C and SmnM194R, were 
identified in type I SMA patients (Clermont et al., 2004; Wirth et al., 1999). The third 
severe allele in our analysis, SmnG206S, was found in a type III SMA patient, however, the 
number of SMN2 copies in that patient’s genome is unknown (Wirth et al., 2000). SMN2 
is a primary modifier of SMA severity and hence it leaves open the possibility that 
SmnG206S is also a severe mutation in humans. At the other end of the spectrum, SmnD20V 
is a mild mutation (over 50% eclosion rate), and its human counterpart, SMND44V, was 
isolated from a patient with type IIIb SMA (Sun et al., 2005). In contrast, the other 
mutations with mild phenotypes in flies, SmnI93F and SmnF70S, were identified in patients 
with type I SMA and bearing low SMN2 copy numbers. The inverse is true for SmnY107C, 
which in flies is of intermediate severity, but was isolated in a type III SMA patient with 
two copies of SMN2 (Prior et al., 2007). This apparent discordance between the fly and 
human phenotypes highlights an advantage of the Drosophila system in studying the 
nature of these mutations. As the genetic background of SMA patients is not isogenic, the 
severity of the disease is likely to be affected by the presence of modifier genes, masking 
the ‘true’ nature of the mutation.  In addition, most of these mutations have been 
observed in only one or two patients. In our model, we have analyzed all the point 
mutations on a highly similar genetic background, thus allowing for better comparison of 
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mutant alleles. Therefore, we believe that the fly system may give a more accurate 
representation of the severity of SMA patient mutations.  
We have modeled SMA mutations that affect the major domains of SMN: the 
Gemin2 binding region, Tudor domain and the YG box. The most severe fly phenotypes 
were the result of mutations in the YG box of SMN. Surprisingly, the mutation affecting 
dGemin2 binding (dSMN(D20V)) displays a mild phenotype, and most of the other 
mutations in the Tudor domain are also relatively mild. The Tudor domain has been 
documented to be important for binding to Sm proteins in mammalian cells, however, 
there are also data suggesting that it is not essential for SMN function in cell culture 
(Wang et al., 2001). Furthermore, the trypanosome and the fission yeast SMN proteins 
seem to be missing the Tudor domain entirely (Owen et al., 2000; Paushkin et al., 2000). 
Collectively, these data suggest that the YG box is more important for SMN function 
than the Tudor domain. This is also consistent with observations in the mammalian 
system that the ability of SMN to oligomerize correlates with the severity of the resulting 
SMA phenotype (Lorson et al, 1998). Some mutations in the Tudor domain have also 
been identified in SMA type I and II patients (Fig. 3.5D). This could indicate 
evolutionary differences in the contribution of domains to SMN function. However, as 
noted previously, discordance between the fly and human phenotypes could also result 
from genetic background effects that complicate the human phenotype.  
Incomplete dominance of Smn mutations 
SMA patient mutations show a recessive mode of inheritance in humans. 
Surprisingly, when we co-expressed mutant Smn transgenes with a WT transgene, we 
observed an intermediate phenotype for several mutants. We hypothesize that the reason 
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the Smn mutations do not behave in a recessive manner in this system is due to the low 
levels of dSMN produced by the transgenes. As discussed earlier, the amount of dSMN 
produced by the WT transgene is likely to be just enough to rescue the null phenotype to 
~65-70% viability. Therefore, any further decrease would give an intermediate level of 
rescue. Preliminary pulldown experiments indicate that the mutant dSMN proteins retain 
the ability to bind the WT protein (Fig. S3.1). Thus, in flies expressing both proteins, the 
mutant and WT proteins would likely bind each other. Therefore, there will be homo-
oligomers of WT and mutant dSMN as well as hetero-oligomers of WT-mutant protein in 
these flies (Fig. 3.6). The mutant homo-oligomers and hetero-oligomers may be non-
functional or semi-functional depending on the nature of the mutation. Thus, the total 
amount of functional WT complexes would be reduced in these flies compared to flies 
expressing one copy of the WT transgene alone. Hence, the phenotype of the hetero-
allelic animals is a reflection of the level of functionality of the mutant homo-oligomers 
and WT-mutant hetero-oligomers. In human SMA carriers there is presumably an 
abundance of SMN, in excess of what is required for normal function (Zhang et al, 2008). 
Thus, reduction of functional complexes due to the presence of a mutant SMN protein 
may not produce a phenotype. We can test this hypothesis by using a strong promoter to 
over-express WT and mutant dSMN in flies. Under conditions where the transgenic 
protein levels will not be limiting, we expect the mutations in Smn will be recessive.   
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Figure 3.6. Model of incomplete dominance of Smn point mutations when co-expressed 
with SmnWT. A. When the WT protein is expressed alone, all of it is functional. This is 
just sufficient to rescue the viability of Smn null flies. B. When WT and mutant (Mut.) 
dSMN proteins are co-expressed (by crossing SmnWT with SmnMut on an Smn null 
background), the proteins will likely interact with each other giving rise to three different 
types of complexes. The WT homo-oligomer consisting of just WT dSMN will be fully 
functional. The WT-mutant hetero-oligomer will have both WT and mutant proteins and, 
hence, may be functional, semi-functional or non-functional. Similarly, a mutant homo-










The incomplete dominance phenomenon could give us insights into the 
mechanism of action of some of these mutants. A relatively high level of rescue was 
observed when the mutation SmnV72G, which causes early pupal lethality, was co-
expressed with SmnWT. This suggests that even though dSMN(V72G) is functionally 
compromised when on its own, the mutant protein has little effect on function when 
incorporated into complexes with dSMN(WT). On the other hand, the dSMN(T205I) 
protein appears to compromise the function of WT-mutant oligomers significantly as the 
level of rescue when SmnT205I is expressed alone or co-expressed with SmnWT is similar. 
The dSMN mutant proteins M194R, Y203C and G206S have a severe phenotype and are 
unstable. Due to their profound effect on the stability of dSMN, it is difficult to decipher 
whether these mutations perturb any specific functions of dSMN. When co-expressed 
with the WT protein, these mutations show greater rescue of viability (~8-16%), 
however, this is significantly lower than the level of rescue observed for WT protein 
alone. This indicates that the WT-mutant hetero-oligomeric complexes are at best semi-
functional. It is likely that entering into complexes with WT dSMN stabilizes the mutant 
proteins (Burnett et al, 2009). Therefore, assuming the WT-mutant complexes are stable, 
it suggests that the mutant residues must be important for another function/interaction of 
dSMN. Thus, co-expressing these mutants with WT dSMN can separate their effect on 
stability from their effects on other SMN functions, allowing us to study defects in the 
latter.  
In conclusion, we have established an allelic series of SMN mutations in 
Drosophila that are derived from disease-causing mutations in humans. These flies reflect 
the entire range of phenotypic severity observed in SMA patients. Our preliminary 
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analyses indicate that the mechanism of action of many of the SMA missense mutations 
may be conserved in Drosophila. Further characterization of these lines including 
analysis of motor function through locomotion assays, longevity assays and mutant 
complementation analysis is needed. At present these analyses are being conducted in the 
absence of wild-type protein alone in order to understand the effect of the mutation 
without confounding factors. In SMA patients, however, there is always a small fraction 
of wild-type SMN being produced from the SMN2 gene. We also have the ability to 
model this condition by expressing a very low level of WT SMN from the 68A4 insertion 
(Fig. S3.3) site along with the mutant transgenes inserted at 86Fb. Thus, the new 
Drosophila models of SMA we have described provide a versatile set of tools with which 
to elucidate the biology and etiology of SMA.  
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Supplementary Data 
Table S3.1. Summary of known human SMN binding proteins tested for interaction with 
fly dSMN. 
 
Human SMN binding partner Comment 
Alpha-actinin Interaction not reproducible 
Profilin (Chickadee) No interaction; reported interaction weak 
even with human SMN 
Hsp27 (potential alpha-B-crystallin homolog) No interaction 
l(2)efl (potential alpha-B-crystallin homolog) No interaction 
Hsp22 (potential alpha-B-crystallin homolog) No interaction 
Dan (putative Gemin4 homolog) No interaction 
Unrip No interaction 
Coilin Weak interaction; no defects in interaction 
with any SMN mutant tested 
SmB Weak interaction with overexpressed GFP-
SmB, none with endogenous 
Zpr1 No interaction; interaction between human 
SMN and Zpr1 is serum dependent, thus 
conditions may need to be optimized to 
detect interaction with fly proteins 
Fimbrin (Plastin3 homolog) No interaction 
  
  
Figure S3.1. dSMN mutations defective in self
bind WT dSMN. Lysates from S2 cells co
and Myc-tagged WT Smn were immunoprecipitated with anti
amount of Myc-dSMN(WT) co
slight decrease that is seen Myc









-oligomerization still retain the ability to 
-transfected with FLAG-tagged mutant 
-FLAG antibody, and the 
-precipitating was visualized by western blotting. The 
-dSMN(WT) co-precipitated by FLAG-dSMN(T205I) 
Smn 
 Figure S3.2. Design of crosses used to
(depicted as 86Fattp) and the PhiC31 Integrase (Int) on the X chromosome into one 
background. The resulting flies were used to inject transgenes. The Integrase was crossed 
out of the transgenic flies.  
 
Figure S3.3. Levels of dSMN expressed from WT transge
with insertion at 68A4 (attP2) site. Three different founder lines for the 68A4 site are 
shown as #1, #2 and #3. Tubulin is used as a loading control.
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 bring SmnX7 mutation, the 86Fb attP insertion site 




 CHAPTER IV 
Conclusions and Future Directions 
Spinal Muscular Atrophy and snRNP biogenesis  
Ever since a role for SMN was described in the life cycle of spliceosomal 
snRNPs, this process has been scrutinised both in vitro and in vivo, in cell culture and in 
model organisms, in an attempt to establish a link to the etiology of SMA. The results of 
these investigations have revealed some positive correlations between snRNP biogenesis 
and SMA, as well as negative correlations. Thus, the nature of the relationship between 
snRNP biogenesis and SMA has remained elusive.  
We launched our own investigation into this question using Drosophila models of 
SMA (detailed in Chapter II). We observed a surprisingly mild reduction in the levels of 
most of the spliceosomal Sm-class snRNAs in Smn null animals, at a time point when 
dSMN protein was not detectable. The most affected snRNAs were those that comprised 
the minor spliceosome. It is possible that large decreases in snRNA levels would cause 
immediate lethality, and hence would not be evident unless we assayed animals that are 
near death. Surprisingly, we noticed that rescue of the null animals with a wild-type Smn 
transgene did not restore the majority of snRNAs to the levels present in control animals. 
These results were initially perplexing, however, we hypothesized that the low level of 
transgene expression in our system may be insufficient to rescue snRNP levels. However, 
the transgene showed a high level of rescue of Smn null animals (~70%). Thus, the low 
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expression of dSMN effectively uncouples snRNA expression levels from organismal 
viability and locomotion defects.  
These findings lead us to question the significance of previously reported snRNA 
depletions in models of SMN deficiency. In mouse models of SMA, snRNA levels are 
reduced, with minor-class snRNAs being preferentially affected (Gabanella et al, 2007; 
Zhang et al, 2008). Carrel et al (2006) and Workman et al (2009) have also reported a 
positive correlation of snRNP assembly activity, snRNA levels and the severity of Smn 
mutant phenotype in SMA model organisms. Indeed, Workman et al (2009) also showed 
that low snRNA levels in Smn null mice could be rescued by expression of Smn. 
However, the expression of transgenic protein in this case was similar to that of a 
heterozygous carrier mouse. These correlations have been interpreted as re-enforcing a 
snRNP-centric view of SMA etiology. Our observations in Drosophila, however, argue 
that these correlations may not indicate a cause and effect relationship between snRNP 
biogenesis defects and SMA.  
Gabanella et al. (2007) also reported the intriguing observation that even though 
the snRNP assembly activity of lysates from SMA patient cells was reduced significantly, 
steady state snRNA levels in these cells were not affected. This finding suggests that the 
residual capacity for snRNP assembly in these lysates was sufficient to maintain a normal 
level of snRNAs. Previously, Pessa et al. (2006) reported that NIH-3T3-D1 cells had a 
five-fold reduction in U4atac snRNA as compared to L-929 cells, however, the 3T3-D1 
cells did not display significant perturbations in splicing of endogenous minor-class 
introns. These findings, along with our observations, indicate that there is considerable 
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tolerance in biological systems to alterations in essential processes, such as the biogenesis 
of spliceosomal snRNPs.  
Given that snRNA levels were not restored in WT transgenic rescue flies, we 
were not entirely surprised that we uncovered no major defects in the splicing of minor-
class intron containing mRNAs in Smn null flies. Unlike mice and humans, Drosophila 
have only twenty introns that are predicted as substrates for the minor-spliceosome. We 
assayed eighteen of the twenty genes that encode these introns, and definitively 
concluded that minor-intron splicing is not perturbed in Smn null flies. We conducted this 
analysis in larvae harvested just prior to the start of the lethal phase, but after the onset of 
locomotor problems. Thus, we can also conclude that global minor-intron splicing defects 
are not the cause of lethality in these animals.  
How does this finding in Drosophila relate to the human disorder? Several groups 
have established Drosophila as a viable organism in which to model SMA (Chan et al, 
2003; Rajendra et al, 2007; Chang et al, 2008). Smn is an essential gene in flies and 
dSMN’s function in snRNP biogenesis is also conserved. Our phenotypic analysis in 
Chapter II, and those of others also show that Smn null animals display locomotor defects 
suggestive of neuromuscular problems. Furthermore, the analysis of SMA-causing point 
mutations in dSMN (Chapter III) has revealed that they behave in a manner similar to the 
human mutant counterparts on a molecular level. In addition, flies carrying these 
mutations also recapitulate the full range of phenotypic severity observed in SMA 
patients. Therefore, it is likely that pathological mechanisms that result in SMA are 
similar in flies and humans. Thus, we believe that snRNP biogenesis defects in humans is 
not likely to be a primary cause of SMA.    
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One of the long-standing hypotheses to explain the neuromuscular specificity of 
SMA is that defects in snRNP levels could preferentially affect certain tissues more than 
others. Although we showed compelling data uncoupling snRNP biogenesis and splicing 
defects from the etiology of SMA on a global scale, our data do not address these defects 
on a tissue-specific level. Therefore, we cannot discount that splicing of minor-class 
introns in critical tissues is unaffected in Smn mutants. However, this caveat is next to 
impossible to address comprehensively, as the specificity could extend beyond tissue 
types to individual cell types. 
One way to understand whether a pathway may be affected by a given mutation, 
such as in SMN1, is to compare the phenotype of the mutation with a known mutant in 
the pathway of interest, such as a mutation in a spliceosomal snRNA. Recently, 
hypomorphic mutations in human U4atac snRNA were linked to microcephalic 
osteodysplastic primordial dwarfism I (MOPD I), also called Taybi-Linder syndrome 
(TALS), in affected individuals from two different populations (Edery et al, 2011; He et 
al, 2011). Symptoms of MOPD I patients include intrauterine and post-natal growth 
retardation, dwarfism, microcephaly (abnormally small head), skeletal dysplasia (bone 
growth defects), brain defects, intellectual disability and death in early infancy or 
childhood (Taybi, 1967; Pierce et al., 2012). Researchers reported defects in the splicing 
of several minor-class intron containing mRNAs in MOPD I patients. However, not all 
minor-class mRNAs were affected, presumably due to the hypomorphic nature of the 
mutation that did not completely abrogate the functions of U4atac. Importantly, the 
phenotype of MOPD I is strikingly distinct from SMA. The former has a more severe 
phenotype that is indicative of disruptions to almost all developmental pathways in 
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affected individuals. SMA manifests as a primarily neuromuscular disease, and SMA 
patients are of normal or above average intellect (Crawford and Pardo, 1996). If snRNP 
biogenesis defects were central to the SMA phenotype, we would expect to see at least 
some symptomatic similarities between SMA and MOPD I. The MOPD I phenotype 
makes a compelling argument against the involvement of minor-class snRNP defects in 
the pathophysiology of SMA. The minor-class snRNA levels were more severely affected 
in Smn mutant animals compared to the major-class snRNAs, thus implying that major-
class snRNP defects are also not likely to be primary to SMA pathology.      
Uncovering additional functions of SMN, or pathways that are involved in SMA 
etiology, is the obvious next step. A number of alternative functions for SMN have been 
put forward. A role for SMN in actin cytoskeletal dynamics is one strong contender, as 
several lines of evidence have uncovered connections between SMN and proteins 
involved in actin homeostasis and function (Rossoll et al, 2003; Shafey et al, 2005; 
Rajendra et al, 2007; Walker et al, 2008; Bowerman et al, 2009; Oprea et al, 2008). 
Numerous studies have also implicated SMN in functions at the neuromuscular junction 
(NMJ) in mice (Kariya et al., 2008; Murray et al., 2008; Kong et al., 2009; Michaud et 
al., 2010; Voigt et al., 2010; Dachs et al., 2011), however the extent of NMJ defects in 
Drosophila Smn mutants is unclear.  Previously, Chan et al (2003) observed an 
enlargement of boutons at the larval NMJs of Smn null mutants with no difference in 
bouton numbers. More recently, Chang et al (2008) reported a decrease in bouton 
numbers in Smn null flies along with strong localization of SMN to wild-type NMJs. 
Despite using three different antibodies against dSMN, we have failed to detect more 
than a faint accumulation of SMN at the NMJ in flies (data not shown). Further, the NMJ 
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defects observed by Chang et al (2008) may be the result of a second-site mutation, as 
other Smn null alleles in the fly do not show NMJ defects (B.McCabe, personal 
communication). However, several groups have confirmed the presence of NMJ defects 
in SMA mouse models. These defects can also arise from disruptions to the actin 
cytoskeleton at the synapse (Jablonka et al., 2007).  
Due to the complexity of functions in which SMN has been implicated, a genome-
scale approach to this problem would be useful. The molecular function of SMN is in the 
assembly of RNPs, therefore SMN may be involved in biogenesis of RNPs other than 
splicing/spliceosomal snRNPs. Recent research in our lab has revealed that Sm proteins 
co-purify with specific mRNAs from Drosophila ovaries and S2 cells, presenting these 
mRNAs as potential candidates for assembly by SMN (Zhipeng, et al. unpublished). 
RNA sequencing of Smn mutants could reveal other RNAs that are affected either 
directly or indirectly by the loss of SMN. It is important that the sequencing be conducted 
on larvae before they enter the lethal phase in order to ensure that the results are 
meaningful to the etiology of the disorder, rather than reflecting the effect of disease 
progression. RNA sequencing will provide a dataset that can also be mined for any other 
defects, such as those in alternative splicing in Smn mutants. We hypothesize that the 
T205I mutation in dSMN, described in Chapter II, may abrogate or reduce a key 
interaction between dSMN and some unknown protein. We can investigate this by 
purifying mutant and wild-type complexes from transgenic flies, and using mass 
spectrometry to identify, compare and contrast co-purifying proteins. A subset of dSMN 
point mutations that produce distinct phenotypes (severe, intermediate and mild) can also 
be assayed with both proteomics and RNA sequencing. As all these mutations are known 
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to cause SMA in humans, changes in binding partners or RNA levels common to all the 
mutants, and that are also restored in the WT rescue flies, would be of interest in the 
context of SMA pathology. Since these mutants show a range in phenotypic severity, 
there may be differences in their interactions that would also be interesting.  
A significant advantage of creating Drosophila point mutant models of SMA is 
their potential for use in genetic studies. A classic approach to identify physiological 
pathways that are connected to Smn function is to perform a genetic screen looking for 
suppressors/enhancers of the Smn mutant phenotype. The screen can be conducted by 
crossing flies exclusively expressing a point mutant dSMN with a collection of deficiency 
lines available from the Bloomington stock centre. Deficiencies are available that 
uncover large regions on chromosomes, giving good coverage of the genome, and can 
serve as a primary screen. Chromosomal regions that show interactions can be further 
narrowed down to the genes responsible by using smaller deficiencies and transposon 
insertion lines. As the endogenous Smn gene is on the third chromosome, this screen 
design will not be able analyze deficiencies located on the third chromosome. 
Alternatively, in order to test the whole genome for genes that interact with Smn, we 
would need to use an RNAi allele targeting Smn mRNA for the screen, instead of an Smn 
point mutation. We can then validate the genes identified as interactors with point mutant 
alleles of Smn. There are RNAi alleles available for Smn from the Transgenic RNAi 
Project (TRiP) at Harvard Medical School that could potentially be useful in a genetic 
screen.   
If we were to conduct a genetic screen using an Smn point mutant, the SmnV72G 
mutant may be an ideal candidate. SmnV72G shows 100% lethality at pupal stages, with 
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very little death at the larval stage. The intermediate lethality of SmnV72G is advantageous 
over a severe mutant such as an Smn null mutant, as it allows for easy identification of 
both enhancers and suppressors of the phenotype. Enhancers would be identified as any 
interactors that cause lethality at larval stages, and suppressors would be interactors that 
extend the life of the mutants to pharate adult/adult stages. Thus, using SmnV72G mutant 
for the screen can maximize the number of genetic interactors we uncover. Furthermore, 
the phenotypic readout from the screen would be relatively quick and simple to interpret 
as it does not require dissections, only observation of a change in the lethal stage. Genes 
identified as interactors can then be tested with other Smn point mutants. The mutations 
we have created were derived from SMA patients, therefore, genes that interact similarly 
with all the mutations would be of particular interest to SMA pathophysiology. It is 
possible that some genetic interactions will be unique to the SmnV72G mutation, which 
would also be interesting. For the same reasons outlined above, an RNAi allele that 
targets Smn would also work well in a genetic screen if it causes lethality at the pupal 
stage.        
Smn and Gemins 
 Shpargel et al (2009) reported a striking decrease in dSMN levels in the absence 
of dGemin3 in Drosophila. At the time it was unclear whether this was a direct 
consequence of the loss of interaction with dGemin3 or an indirect result of dGemin3 
depletion. We show in Chapter III that two SMA mutations in dSMN (Y203C and 
G206S) that disrupt the interaction with dGemin3 are also unstable in vivo. This result 
confirms the original observation by Shpargel and colleagues, and definitively 
demonstrates that abrogating the interaction between dSMN and dGemin3 leads to SMN 
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instability. The Y203C and G206S mutations also display defects in self-oligomerization. 
Thus, it is possible that these mutations fail to bind dGemin3 because of an inability to 
oligomerize. However, another dSMN mutation (T205I) displays oligomerization defects, 
yet retains the ability to bind dGemin3. Thus it is unlikely that interaction between 
dGemin3 and dSMN is dependent on dSMN oligomerization.  In addition, experiments 
with the human counterpart of the Y203C mutation (Y272C) show that its failure to 
interact with dGemin3 is independent of its ability to oligomerize (Charroux et al, 1999).  
The mechanism of how dGemin3 interaction may impact the stability of dSMN is 
not yet understood. The major factor known to affect the stability of SMN is its 
oligomerization state. SMN that is unable to oligomerize has a shorter half-life than SMN 
that enters into a complex (Burnett et al., 2009).  Thus, one hypothesis is that interaction 
with dGemin3 is an important factor in dSMN oligomerization. In the absence of this 
interaction, dSMN may be unable to oligomerize efficiently and is degraded (Fig. 4.1). In 
this scenario, we would expect to see a correlation between the severity of the defect in 
self-oligomerization of Y203C and G206S, and the stability of these mutants. The 
experiments we have conducted to assay the oligomerization defect (co-
immunoprecipitation) and in vivo stability (level of protein), were not quantitative. 
However, taken at face value, the self-oligomerization defect of Y203C seems more 
severe than G206S but both proteins show a more or less similar level of reduction in 
vivo. Therefore, it is possible that the effect of dGemin3 on dSMN stability is 
mechanistically independent of oligomerization. Even if dGemin3 does influence dSMN 
oligomerization, there must be other determinants since overexpression of YFP-dSMN in 
a dGemin3 mutant background restores endogenous dSMN levels (Shpargel et al, 2009). 
 In addition, the T205I mutation in dSMN shows defects in self
independent of dGemin3.  
 
 
Figure 4.1. A model for how dGemin3 
of dSMN. The mutants, Y203C and 
oligomerization and in binding to dGemin3
formation, or stabilize dSMN oligomers. Therefore, failure to interact with dGemin3 can 
disrupt efficient or stable oligomer form
must also be other determinants of oligomerization because the T205I mutation also 
disrupts oligomerization of dSMN but is able to interact with dGemin3. 
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Further characterization of the oligomerization defects using in vitro assays, and 
the stability of the Y203C, G206S and T205I mutant proteins in a quantitative manner 
will help distinguish between the two alternative mechanisms proposed above. We can 
also test whether dGemin3 plays a role in dSMN oligomerization by determining whether 
dSMN forms higher order complexes in the absence of dGemin3. dGemin3 can be 
knocked down in S2 cells and sucrose gradient fractionation can be used to obtain the 
sedimentation profile of dSMN, and thus provide a rough measure of its oligomerization 
state. A shift of the sedimentation profile to a lower fraction when compared to the 
control would indicate that dSMN is not incorporated into oligomeric complexes, thus 
suggesting that dGemin3 impacts the oligomerization of dSMN. A potential problem with 
this approach is that dSMN is co-depleted when dGemin3 is knocked down. SMN is 
thought to be ubiquitinated and degraded via the proteasome pathway (Burnett et al, 
2009). Therefore, the sedimentation assay can also be performed in the presence of a 
proteasome inhibitor to stabilize dSMN levels. Alternatively, dGemin3 could influence 
dSMN stability by masking a potential degron sequence that targets dSMN for 
degradation, or by stabilizing the association of dGemin2 and dSMN in vivo. It would be 
interesting to test if dGemin2 levels are disrupted by removal of dGemin3 or by depletion 
of dSMN, or vice versa. To address these questions in vivo, we need to develop 
antibodies against the Gemins. Studies of non-snRNP biogenesis related functions of 
SMN have indicated that the Gemins may also participate in the alternate roles in which 
SMN has been implicated (Zhang et al., 2006; Walker et al., 2008; Todd et al., 2010). In 
addition, our observation of the dramatic impact of dGemin3 on the stability of dSMN 
also suggests that it is important for all functions of dSMN. Hence, antibodies against 
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dGemin3 and dGemin2 may be important tools in future experiments exploring the 
functions of dSMN.  
Is the positive effect of Gemin3 on SMN stability unique to Drosophila or is it 
conserved in mammals? An investigation by Burnett et al (2009) into the stability of 
SMN found a strong correlation between SMN stability and its incorporation into 
complexes. These investigators also demonstrated that the oligomerization deficient 
human SMN mutations, Y272C, G279V and SMN∆7, had significantly shorter half-lives 
than wild-type SMN. Such parameters were defined using human cell-based pulse-chase 
assays. Interestingly, both Y272C and SMN∆7 are known to have defects in binding 
Gemin3 (Charroux et al, 1999). Thus, it is tempting to speculate that the defect in binding 
Gemin3 could be contributing to the instability of the Y272C and SMN∆7 mutants in 
human cells as well. To the extent of our knowledge, the human G279V mutation has not 
been tested for binding to Gemin3. The equivalent mutation in flies, G210V, does not 
show defects in binding Gemin3 or in self-oligomerization, and also appears to be stable 
in vivo. The difference in the behavior of this mutation in humans and flies suggests that 
this residue may have developed a more important role in SMN function in mammals. 
The fact that two out of three human SMN mutations that are unstable also fail to bind 
Gemin3 leaves open the possibility that Gemin3 may stabilize SMN in mammalian cells 
as well.  
SMN, ecdysone and insulin signalling 
It is now apparent that SMN function is not merely required in motor neurons and 
muscles, even though these tissues show the earliest signs of pathology in patients (Park 
et al., 2010; Hua et al., 2011). In a recent study, researchers found that restoring SMN 
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levels systemically was much more efficacious in extending the life span of a severe 
SMA mouse model (up to 108 days), compared to restoring levels in the central nervous 
system alone (up to 16 days) (Hua et al, 2011). These researchers used an antisense 
oligonucleotide to increase the production of full length SMN from SMN2. This suggests 
that SMN function in peripheral tissues is a critical factor that must be accounted for in 
any model of SMA pathology.  
Previous research addressed the tissue-specific requirement for SMN by using the 
UAS-GAL4 system to either rescue SMN levels in neurons and muscles of Smn null 
animals, or to deplete these tissues of dSMN. Two such studies conducted in Drosophila 
showed that SMN expression in both neuronal and muscle tissue was needed for viability 
(Chan et al, 2003; Chang et al; 2008). A study along similar lines in mice showed data 
that agreed with the observations in the fly (Gavrilina et al; 2007). The caveat with these 
studies is the potential for leaky expression in peripheral tissues. We know that in 
mammals and in Drosophila, a very small amount of SMN (~5-15%) is sufficient for 
function (Zhang et al., 2008). Hence, even a low level of leaky expression in these 
experiments could confound interpretation of the results.    
As described in Chapter II, Smn null mutants in Drosophila die as larvae. The 
primary lethal phase extends over two days; the remaining larvae survive for several 
additional days without pupating. These long-lived larvae also never enter the wandering 
stage. Interestingly, Smn null larvae do not have any imaginal discs visible under the 
dissecting microscope (unpublished observations). It is not known if they are completely 
devoid of discs (‘discless’) or have discs that are too small to be seen without the use of 
specific markers (Szabad et al., 1982). Many discless or small disc mutant larvae (after a 
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lengthy larval period) go on to pupate suggesting that the presence of discs is not 
necessary for larval development (Shearn et al., 1971). Therefore the larval lethal 
phenotype of Smn null mutants cannot be explained simply from the absence of imaginal 
discs (or small discs). It is likely that the imaginal disc defect is a secondary effect of 
disruption to process(s) that are essential to larval development.  
Our preliminary observations show that a subset of Smn null larvae appear to be 
in the midst of molting when they die, with the old larval cuticle still attached. This is 
similar to the phenotype described in mutants of the putative Gemin5 homolog, Rigor 
Mortis (rig). rig mutants also show an extended larval phase with many larvae dying 
while in the process of molting (Gates et al., 2004). However, rig mutant larvae become 
stiff just before dying, a phenotype that we have not observed in Smn null mutants. Also, 
in contrast to Smn mutants, a small fraction of rig mutants form prepupae before dying. 
Therefore, the Smn phenotype is more severe. The phenotype of rig mutants is consistent 
with a defect in ecdysone signalling. Gates et al (2004) characterized Rig as a nuclear 
receptor binding protein that acts in the ecdysone signalling pathway, downstream of 
ecdysone synthesis and release. Although bioinformatic analysis shows Rig as the closest 
putative ortholog of Gemin5 (Kroiss et al; 2008), Rig’s function in snRNP biogenesis has 
not been validated. Tests for an interaction between Gemin5 and SMN have also come up 
negative (Kroiss et al, 2008). However, in a recent study Rig was localized to U-snRNP 
rich cytoplasmic bodies, called U-bodies, along with dSMN and dGemin3 in Drosophila 
ovaries (Cauchi et al., 2010). This suggests that there may yet be a common function for 
Rig and dSMN, and that their interaction may be transient or time/tissue specific. The 
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similarities between rig and Smn mutants and their close relationship in other organisms 
also suggest a disruption of hormonal regulation in the pathology of Smn mutants.  
Recently, Hua and colleagues (2011) showed evidence of disruption to the insulin 
growth factor (IGF) signalling pathway in a severe SMA mouse model. These mice had 
greatly reduced or undetectable serum levels of insulin growth factor 1 (IGF1). The 
researchers showed that this reduction is likely to be caused by reduced IGF-binding-
protein acid labile subunit (IGFALS) expression in these mice. IGFALS is thought to 
bind IGF1 and increase its half-life. The levels of IGFALS are reduced early in these 
mice, suggesting that this is not an effect of disease progression, but could be a cause. 
Both the levels of IGFLAS and IGF1 can be rescued by restoring SMN levels. Evidence 
for dysregulation of the IGF1 system has also been reported in SMA type III patients, and 
has been implicated in the pathology of other neuromuscular disorders (Furling et al., 
1999; Millino et al., 2009).  
In Drosophila, the ecdysone signalling pathway and insulin/IGF signalling system 
(IIS) are intimately connected (Fig. 4.2). The IIS system is thought to be involved in 
regulating ecdysone release, and linking the hormonal signalling pathway to nutritional 
inputs (Edgar, 2006). Some loss of function mutants in the IIS system in Drosophila are 
characterized by delay in reaching critical size (minimum size required for pupation) 
during larval development, smaller imaginal discs, delay in eclosion and small body size 
of the adult. Strong mutations in other components of this pathway, such as the insulin 
receptor (InR) are embryonic lethal (Garofalo, 2002). Interestingly, when we rescued Smn 
animals with low levels of WT dSMN, we observed a delay (~24 hours) in entry into 
pupation and subsequently in eclosion. The delay may be during the late larval period, as 
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they seem to enter third instar at around the same time as controls. These rescued larvae 
and pupae are smaller than controls suggesting that they may take longer to reach the size 
requirements for pupation. The Smn null larvae also show developmental delay and are 
much smaller in size compared to age-matched controls. Together with the reduction in 
IGF1 in SMA mice and similarity to the phenotype of rig mutants, these observations 
indicate that perturbations in IIS and consequently hormonal signalling pathways may 












Figure 4.2. A summary of the interconnectivity of the insulin signalling system (ISS) 
with the hormone signalling pathway. Figure is taken from Edgar et al, 2006. ILP – 
insulin like peptide; mNSC – medial neurosecretory cells; PG – prothoracic gland; 20E – 
20-hydroxyecdysone, the active form of ecdysone; PTTH – prothoracicotropic hormone; 





The IIS pathway is important for growth in organisms, including insects. It has 
been documented that this pathway along with the hormonal signalling pathway regulates 
early imaginal disc growth in insects (Bryant, 2001; Truman et al., 2006). Thus, 
perturbations in these systems could lead to loss of imaginal discs. An early ecdysone 
response gene is the Broad Complex (BRC), which encodes at least three different 
proteins brought about by alternative splicing, and is essential for metamorphosis of the 
larva. Mutations in one of the BRC encoded proteins results in degeneration of dorsal 
ventral indirect flight muscles (DVMs) in the Drosophila thorax due to problems in 
muscle attachment (Sandstrom et al., 1997). Our lab has characterized a hypomorphic 
Smn mutant, SmnE33, that shows a selective reduction of SMN levels in the thorax. 
Interestingly, SmnE33 flies are unable to fly or jump, and have severe muscular atrophy of 
DVMs (Rajendra et al, 2007). This phenotype could also arise from dysregulation of the 
ecdysone signalling pathway. It would be interesting to see if SmnE33 flies show muscle 
attachment defects as well.  
We can test Smn null larvae for defects in the IIS/ecdysone signalling pathways. 
E74 is an early ecdysone response gene that encodes two mRNAs, E74A and E74B, from 
different transcription start sites (Karim et al., 1991).  Low levels of ecdysone induce 
expression of E74B while high levels repress E74B, and induce E74A expression. 
Therefore, a disruption to the ratio of these mRNAs in Smn mutant animals compared to 
controls would be indicative of a disruption in ecdysone signalling (Gates et al, 2004). As 
the levels of IGF1 were reduced in a mouse model of SMA, we can test for a similar 
defect in the levels of one of the eight insulin homologs, insulin like peptide (DLIP), in 
Smn null larvae (Edgar, 2006). Furthermore, an in depth characterization of the lethal 
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phenotype of Smn null animals, such as examining their mouth hooks to determine if they 
all die at the same instar, and monitoring whether they feed as well as wild-type controls 
will be useful. Since the IIS pathway is highly responsive to perturbations in nutritional 
intake, it is important to ascertain whether the feeding ability of Smn mutants is affected, 
and thus could be leading to the phenotypes observed. The Smn null animals show a more 
severe phenotype than many of the mutants in the IIS pathway, excluding the insulin 
receptor mutants. Smn mutants also show significant larval locomotion defects, which 
have not been documented for mutants in IIS pathways. In addition, Smn null larvae 
never exhibit the wandering behavior, even the long-lived ones. They also never form 
pseudopupae (some weaker alleles of Smn can form pseudopupae) whereas most mutants 
in the IIS pathway are viable. These differences between Smn and IIS pathway mutants 
suggest that there are likely to be other pathways that also contribute to the phenotype of 
Smn mutants.  
Summary 
The ‘holy grail’ of SMA research is to discover which function of SMN lies at the 
heart of this disease. The answer to this question will be important not only for the 
treatment of SMA, but also for the advancement of our knowledge of fundamental 
concepts in RNA biology and neuromuscular development. A large segment of the SMA 
biology field has focused on understanding how, and if, defects in spliceosomal snRNP 
biogenesis can lead to a neuromuscular disorder. Using Drosophila models of SMA, we 
have shown that it is possible to uncouple deficiencies in snRNP levels from the viability 
and locomotor defects that characterize Smn mutants. We also demonstrated that splicing 
of mRNAs, the functional readout of snRNP activity, is largely unperturbed in the 
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absence of SMN. Our findings strongly suggest that the etiology of SMA lies in snRNP 
biogenesis independent functions of SMN. This work gives the SMA field the impetus to 
explore alternative functions of SMN, and how they may contribute to SMA. This is a 
significant first step, and to continue to understand SMA etiology, we have generated an 
allelic series of new Drosophila SMA models. Through biochemical and genetic studies 
that compare and contrast these models, we can begin to unravel the physiological 
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